REVIEW

The hypocretins/orexins: integrators of multiple physiological functions

Jingcheng Li¹, Zhian Hu¹ and Luis de Lecea²

¹Department of Physiology, Third Military Medical University, Chongqing, China, and

²Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA

Correspondence

Zhian Hu, Department of Physiology, Third Military Medical University, 30 Gaotanyan Street, Chongqing 400038, China.
E-mail: zhianhu@yahoo.com.cn;
Luis de Lecea, Department of Psychiatry and Behavioral Sciences, 1201 Welch Road, Stanford, CA 94305, USA. E-mail: llecea@stanford.edu

Keywords

sleep; arousal; narcolepsy; hypothalamus; addiction; anxiety; stress; neuropeptide

Received

24 March 2013

Revised

16 July 2013

Accepted

2 August 2013

The hypocretins (Hcrts), also known as orexins, are two peptides derived from a single precursor produced in the posterior lateral hypothalamus. Over the past decade, the orexin system has been associated with numerous physiological functions, including sleep/arousal, energy homeostasis, endocrine, visceral functions and pathological states, such as narcolepsy and drug abuse. Here, we review the discovery of Hcrts/orexins and their receptors and propose a hypothesis as to how the orexin system orchestrates these multifaceted physiological functions.

LINKED ARTICLES

This article is part of a themed section on Orexin Receptors. To view the other articles in this section visit <http://dx.doi.org/10.1111/bph.2014.171.issue-2>

Abbreviations

CRF, corticotrophin releasing factor; Hcrts, hypocretin; LH, lateral hypothalamus; NREM, non-rapid eye movement sleep; OX, orexin; PVN, paraventricular nucleus

Introduction: discovery

Gautvik *et al.* (1996) used subtractive hybridization to generate a library of cDNAs representing the most prevalent mRNAs present in the hypothalamus. This list, which contained 43 different sequences, revealed that the hypothalamus specializes in making intercellular signalling molecules, as 40% of the clones encoded neuropeptide transmitters. One of the most frequent cDNA clones encoding the precursor of one such peptide transmitter was called preproorexin (preprohypocretin).

In situ hybridization studies showed that preproorexin mRNA is produced by a discrete group of neurons (~5000 in rodents; 20–50 000 in humans) bilaterally distributed in the lateral posterior hypothalamus (Gautvik *et al.*, 1996; de Lecea *et al.*, 1998). These cells produce a single polypeptide that is processed into two peptides orexin-A (Hcrts-1) and orexin-B (Hcrts-2) of 33 and 28 amino acid residues, which show a seven out of seven sequence match with secretin. Orexin neurons are excitatory, express the vesicular glutamate transporter VGLUT2 (Rosin *et al.*, 2003), and also produce dynorphin (Chou *et al.*, 2001), neuronal activity related pentraxin

(NARP; Reti *et al.*, 2002) and protein delta-like 1 homologue (DLK-1; Meister *et al.*, 2013).

Sakurai *et al.* (1998) identified the same peptides, which they named orexins, as ligands of two orphan GPCRs and determined the chemical sequence of the processed peptides. As per journal guidelines, we refer to the peptides as orexins, but it is clear that the main function of the peptides is not appetite, and we personally prefer the original nomenclature of Hcrts. These two receptors, Hcrts receptor type 1 and Hcrts receptor type 2, also known as OX₁ (orexin 1) and OX₂ receptors, have broad and partially overlapping but a distinct distribution throughout the brain. Orexin-B binds preferentially to OX₂ receptors whereas orexin-A binds with equal affinity to OX₁ and OX₂ receptors. An excellent review of the cell signalling properties of OX (Hcrts) receptors has been recently published elsewhere (Kukkonen, 2013). Drug/molecular target nomenclature throughout this manuscript conforms to BJP's Concise Guide to PHARMACOLOGY (Alexander *et al.*, 2013).

Several OX receptor antagonists have been described (Smart *et al.*, 2001; Gunthorpe *et al.*, 2004). SB-334867 was the first and most widely used compound, and although

initially was claimed to be selective for OX₁ receptors, it blocks binding to both OX receptors at the concentrations used in most studies (3–30 mg·kg⁻¹). Studies on this compound were followed by investigations into several orally bioavailable molecules with high selectivity for OX receptors (McAtee *et al.*, 2004; Brisbare-Roch *et al.*, 2007). More recently, suvorexant, a non-selective OX receptor antagonist, has been successfully used in clinical trials to treat primary insomnia (Winrow *et al.*, 2011).

Despite their restricted location in the lateral hypothalamus (LH), orexin neurons project broadly throughout the whole brain, and can be modulated by multiple humoral signals and neuronal inputs, such as innervation from other hypothalamic areas and the limbic system. These properties suggest that the orexin system may sense the fluctuation of both internal and external environments to orchestrate an appropriate response.

The main inputs to and regulators of orexinergic neurons originate from structures in the limbic system (Sakurai *et al.*, 2005; Yoshida *et al.*, 2006); in addition, humoral signals make the orexin system susceptible to the effects of environmental stimuli and homeostatic states. Based on these inputs, which reflect the needs of an organism in different conditions, the orexin system can act as an integrator of numerous physiological functions, including sleep/arousal states, sensory, locomotion, cognition, energy homeostasis, endocrine and visceral functions.

Physiological roles

Arousal

Soon after the identification of orexins in 1998, two groups demonstrated an association between orexin deficiency and the sleep disorder narcolepsy (Chemelli *et al.*, 1999; Lin *et al.*, 1999; Nishino *et al.*, 2000; 2001; Peyron *et al.*, 2000; Thannickal *et al.*, 2000; Hara *et al.*, 2001). In addition, several studies have shown that OX receptor knockout (KO) mice and mice deficient in OX₂ receptors (Mochizuki *et al.*, 2011) have normal amounts of sleep and wakefulness across the light/dark cycle (Mochizuki *et al.*, 2004; Anaclet *et al.*, 2009) but the stability of these behavioural states is considerably reduced. Dogs with mutations in OX₂ receptors exhibit narcolepsy with cataplexy (Lin *et al.*, 1999). Patients that suffer from narcolepsy with cataplexy have very low levels of orexin-A in their CSF (Nishino *et al.*, 2000; Peyron *et al.*, 2000; Thannickal *et al.*, 2000). These deficits are probably caused by the selective degeneration of orexin cells (rather than a down-regulation of the orexin gene) because other markers that colocalize with orexin are also reduced in narcoleptic patients (Crocker *et al.*, 2005). All of these data clearly demonstrate that orexin signalling is essential for the stability of the arousal state.

The first recordings of orexin neurons *in vitro* indicated that these cells are spontaneously active and respond to numerous stimuli. Studies by Fujiki *et al.* (2001) using microdialysis and Estabrooke *et al.* (2001) using c-Fos mapping revealed a circadian modulation of orexin peptide concentration in the CSF and orexin cell activity respectively. However, due to their very low temporal resolution, these methods did not enable these circadian changes to be monitored precisely.

Parallel studies using juxtacellular recordings in head-fixed or freely moving animals showed that, surprisingly, orexin activity is mostly phasic and precedes sleep to wake transitions (Lee *et al.*, 2005; Mileykovskiy *et al.*, 2005). The question remained as to whether this phasic activity of orexin neurons was permissive or instructive for awakenings. In the first *in vivo* study to investigate the effect of optogenetic photostimulation of orexinergic neurons on the behaviour of animals (Adamantidis *et al.* (2007), it was found that activation of these neurons specifically increases the probability of transitions from sleep to wakefulness. This effect was frequency-dependent as only frequencies >5 Hz increased the probability of the animal waking up. Semi-chronic stimulation of orexin neurons did not significantly increase the amount of non-rapid eye movement (NREM) sleep suggesting that phasic activation of orexin cells is involved in the transition to wakefulness, but not in the maintenance of this state. Optogenetic silencing of orexin neurons induced sleep during the light phase, but not during the dark phase (Tsunematsu *et al.*, 2011). These findings were further validated using a newly developed pharmacogenetic technique (designer receptors exclusively activated by designer drugs; Sasaki *et al.*, 2011) that allows the modulation of neural activity with temporal resolution for several hours. Hence, it is thought that the orexin system acts as a regulator of behaviour states by modulating the arousal threshold (Sutcliffe and de Lecea, 2002), so that a mammal or human can maintain appropriate and adequate wakefulness to cope with fluctuations in the external and internal environments (Figure 1).

The next question we asked was does the existence of two subtypes of receptor account for different aspects of the functions of orexin? Mice deficient in OX₂ receptors display fragmented wakefulness similar to the narcoleptic phenotype, whereas OX₁ receptor-KO mice only show a mild sleep disorder (Willie *et al.*, 2001). However, double, OX₁ and OX₂ receptor-KO mice were found to have more severe deficits in their sleep-wake cycle than OX₂ receptor-KO mice, which exhibited a low level of cataplexy and disruption of REM sleep (Chemelli *et al.*, 1999; Willie *et al.*, 2003). Therefore, it was concluded that both OX₁ and OX₂ receptor are essential for maintaining a stable sleep/wakefulness cycle, with the role of OX₂ receptors being more important (Sakurai, 2007). However, in a recent study it was found that the effects of orexin-A on wakefulness and NREM were attenuated in both OX₁ and OX₂ receptor-KO mice (Mieda *et al.*, 2011). Furthermore, in a recent functional magnetic resonance imaging study, it was shown that an antagonist of OX₂ receptors, but not OX₁ receptors, increased REM, NREM and total sleep time, suggesting that the two receptors have distinct roles in regulating sleep and wakefulness (Gozzi *et al.*, 2011). Also, the recent development of OX receptor selective antagonists showed that blocking OX₁ receptors attenuates the effects of an OX₂ receptor antagonist and revealed a complex interaction between these two receptors (Dugovic *et al.*, 2009). Selective and non-selective OX receptor antagonists have recently completed phase III clinical trials for the treatment of insomnia (Herring *et al.*, 2012), a remarkable achievement for a gene product that was only discovered 15 years ago.

Effectors of orexinergic neurons: the monoamines. Monoaminergic neurons constitute one side in the flip/flop model of

Figure 1

The six schematic drawings show the representative nuclei (or nucleus) involved in the corresponding functions, namely, the structure involved in regulation of sensory information [the posterior hypothalamic area, (PH)], in locomotion [the cuneiform nucleus (CNF) and lateral vestibular nucleus (LVN)], in cognition [the prefrontal cortex (PFC) and hippocampus (Hip)], in energy homeostasis [the arcuate nucleus (ARC)], in endocrine [the paraventricular nucleus of hypothalamus (PVH)] and in visceral functions [the ventrolateral medulla (VLM), pontine Kölliker-Fuse nucleus (KF) and dorsal motor nucleus of the vagus (DMV)].

the sleep-wake cycle (Saper *et al.*, 2010); they excite the neocortex but inhibit sleep centres to promote wakefulness. Importantly, these monoaminergic neurons present in the tuberomammillary nucleus (TMN, histaminergic), locus coeruleus (LC, noradrenergic), dorsal raphe nuclei (DRN, 5-hydroxytryptaminergic) and ventral periaqueductal gray matter (vPAG, dopaminergic) receive dense projections of orexinergic neurons (Peyron *et al.*, 1998; Saper *et al.*, 2005) and, consistent with the various roles of orexin (Marcus *et al.*, 2001), the LC mainly expresses OX_1 receptors, the TMN mainly OX_2 receptors and the DRN expresses both OX_1 and OX_2 receptors. Mieda *et al.* (2011) showed that the effects of i.c.v. orexin-A (Hcrt-1) on wakefulness and NREM sleep are significantly attenuated in both KO mice as compared with wild-type mice, with the effect being substantially larger in OX_2 receptor-KO mice than in OX_1 receptor-KO mice. These results suggest that although the OX_2 receptor-mediated pathway has a pivotal role in the promotion of wakefulness, the OX_1 receptor is also involved in promoting arousal. However, both receptors appear to be similarly involved in REM sleep suppression.

Orexinergic neurons exhibit parallel firing patterns with monoaminergic neurons that exhibit tonic firing during wakefulness especially during active wakefulness, mild firing during slow-wave sleep, and then are silent during REM sleep (Estabrooke *et al.*, 2001; Lee *et al.*, 2005; Mileykovskiy *et al.*,

2005), except during the transition to wakefulness, when intensive firing is observed (Sakurai, 2007). These data are also consistent with the oscillation of extracellular orexin-A levels that peak during the waking state and decrease to about half their maximum levels during sleep (Yoshida *et al.*, 2001; Zeitzer *et al.*, 2003). These observations suggest that the orexin system stabilizes the state of wakefulness by driving the arousal system (Saper *et al.*, 2010).

Indeed, *in vitro* electrophysiological studies showed that orexin activates the TMN histaminergic (Bayer *et al.*, 2001; Eriksson *et al.*, 2001; Huang *et al.*, 2001), LC noradrenergic (Hagan *et al.*, 1999) and DRN 5-hydroxytryptaminergic (Liu *et al.*, 2002) neurons. Furthermore, *in vivo* experiments revealed the involvement of the LC and OX_1 receptors in the LC (Bourgin *et al.*, 2000), as well as the histamine H_1 receptor (Huang *et al.*, 2001) and OX_2 receptor signalling in the TMN (Mochizuki *et al.*, 2011), in orexin-induced arousal. Although, in contrast, recent studies have shown that the orexin-mediated sleep-to-wake transition in mice is not dependent on the histaminergic system (Carter *et al.*, 2009a) and mice deficient in both H_1 receptors and OX_1 receptors display normal sleep/wakefulness patterns (Hondo *et al.*, 2010).

Moreover, Lu and Greco (2006) demonstrated that loss of dopaminergic neurons in vPAG results in a 20% reduction in wakefulness accompanied by an increase in NREM, REM sleep. This finding is supported by a recent report (Kaur

et al., 2009) that demonstrated activation of the orexin-vPAG circuit suppresses REM sleep but not non-REM sleep. Orexinergic neurons also receive inhibitory innervation from noradrenergic (Li *et al.*, 2002), 5-hydroxytryptaminergic (Yamanaka *et al.*, 2003b; Kumar *et al.*, 2007) and dopaminergic (Yamanaka *et al.*, 2006) inputs, whereas histamine has little, if any, effect (Yamanaka *et al.*, 2003b). However, the effect of noradrenergic innervation on the activity of orexinergic neurons remains controversial, as some reports show excitatory effects in rats and others demonstrate an inhibitory action (Grivel *et al.*, 2005).

Orexin activates the monoaminergic neurons (Carter *et al.*, 2012), which project to the LH, basal forebrain, as well as cerebral cortex to exert its arousal effect. This notion is supported by a recent study, which showed that mice deficient in the histamine synthesizing enzyme histidine decarboxylase (HDC $-/-$ mice) but not OX receptor $-/-$ mice exhibit abnormal cortical electroencephalographic activity (Anacleit *et al.*, 2009). Interestingly, optogenetic activation (photostimulation) of orexin neurons is not affected in HDC KO mice (Carter *et al.*, 2009a), suggesting that histamine is not essential for orexin-mediated awakenings.

Furthermore, the cholinergic neurons in the pedunculo-pontine tegmental nucleus/laterodorsal tegmental nucleus (PPT/LDT) fire rapidly during wakefulness and REM sleep but slowly during NREM sleep (Saper *et al.*, 2005), suggesting that they help to maintain cortical activation in the states of wakefulness and REM sleep. Injecting orexin-A into the laterodorsal tegmental nucleus (LDT) results in a significant increase in wakefulness but a decrease of the amount rather than the duration of REM sleep (Xi *et al.*, 2001). In addition, orexin-A has been shown to elicit long-lasting excitation in both cholinergic and non-cholinergic neurons of the LDT (Takahashi *et al.*, 2002). Interestingly, the cholinergic synaptic transmission of LDT neurons is augmented in OX receptor-KO mice, which may induce cataplexy (Kalogiannis *et al.*, 2010). In addition, the (pedunculopontine tegmental nucleus) PPT may also be involved in orexin-induced modulation of wakefulness, as orexin-A has been shown to inhibit the activation of PPT cholinergic neurons, which induces REM sleep onset and atonia (Takakusaki *et al.*, 2004) via GABAergic neurons in substantia nigra pars reticulata and the PPT itself (Takakusaki *et al.*, 2005).

In vitro studies have shown that carbachol, a cholinergic agonist, excites orexinergic neurons (Bayer *et al.*, 2005). In addition, i.c.v. administration of orexin-A (Piper *et al.*, 2000) or its local application into the LC (Bourgin *et al.*, 2000), basal forebrain (España *et al.*, 2001; Thakkar *et al.*, 2001) or lateral preoptic area (Methippara *et al.*, 2000) increases the waking time at the expense of sleep. In summary, orexin-induced arousal is modulated not only by monoaminergic neurons, but also by cholinergic neurons in the PPT/ LDT and basal forebrain.

Importantly, the orexin system may be modulated by the circadian clock and homeostatic states (Deboer *et al.*, 2004; Carter *et al.*, 2009a; Appelbaum *et al.*, 2010). Even though there is no evidence of a direct synaptic connection between the suprachiasmatic nucleus (SCN) and orexin cells, the circadian clock drives the orexin system through the output circuits of the SCN (Deurveilher and Semba, 2005). Additionally, local modulation of orexinergic neurons induced

by orexin release (Li *et al.*, 2002; Yamanaka *et al.*, 2010), melanin-concentrating hormone (MCH) (Rao *et al.*, 2008; Hassani *et al.*, 2009) or neurons expressing an active form of the leptin receptor (Leininger *et al.*, 2011) may also be important in the circadian stabilization of a proper sleep-wake cycle. Modulation of orexin activity by energy homeostasis will be expanded in the Energy homeostasis section. Intrinsic plasticity mechanisms may regulate the firing probability of orexin cells during the day and at night (Appelbaum *et al.*, 2010). During the wakefulness period, tonic excitation of orexin neurons may be enhanced when certain stressors are present, like emotional stimulation, which involves the limbic input (Tsujino and Sakurai, 2009). Adamantidis *et al.* (Adamantidis and de Lecea, 2008a,b) suggested a dual mode of action of orexin: phasic activity lasting 1–10 s that is mostly responsible for the state transitions, and a circadianly-regulated oscillation that encodes superimposed information about metabolic and circadian state.

Sensory

So far, the involvement of orexin in sensory modulation has focused on its role in nociception, in addition to an emerging role in olfaction.

Pain. The analgesic properties of orexin peptides have been well-established with i.v., intrathecal or i.c.v. injection approaches in mouse and rat models of thermal (hot-plate, tail-flick, paw-withdrawal), mechanical (tail pressure, partial sciatic nerve ligation), chemical (formalin, carrageenan, capsaicin and abdominal stretch) nociception and (or) hyperalgesia (Bingham *et al.*, 2001; Yamamoto *et al.*, 2002; 2003a,b). In all of those models, the orexin-induced analgesic effects were suppressed by the OX₁ receptor antagonist SB-334867 but not by naloxone, an opioid receptor inverse agonist, suggesting that regulation of nociception by orexin is independent of the opiate system (Figure 2). In addition to the direct projection of orexin neurons to the spinal cord (van den Pol, 1999), orexin signalling in the posterior hypothalamic area (Bartsch *et al.*, 2004), the pontine reticular nucleus, oral part (Watson *et al.*, 2010), and periaqueductal gray matter have been shown to be important for its antinociceptive effects. Moreover, orexin plays a significant role in the regulation of stress-induced analgesia (SIA), coordinating with the nociceptin/orphanin FQ systems (Xie *et al.*, 2008; Gerashchenko *et al.*, 2011). Consistent with these data, preproorexin KO mice exhibit hyperalgesia and less SIA (Watanabe *et al.*, 2005). The involvement of orexin in pain is also supported by clinical observations, which have shown there is an association between changes in the Ox receptors and headaches (see below) (Rainero *et al.*, 2004) and a recent multicentre case-control study revealed that chronic pain is more common in patients with narcolepsy with cataplexy than in the controls (Dauvilliers *et al.*, 2011).

Olfaction. The participation of orexin in olfactory function is suggested by the presence of orexin neurons and receptors at all levels of the olfactory system, and their ability to modulate the excitability of olfactory sensory and relay neurons (Caillol *et al.*, 2003; Gorojankina *et al.*, 2007). Indeed, i.c.v. injection of orexin-A increases the olfactory sensitivity to

Figure 2

Effect of orexins (Hcrt) on structures involved in locomotion and sensory systems (pain). This diagram summarizes the effects of orexin (Hcrt) on structures involved in locomotion and pain. Orexin regulates locomotor activities and muscle tone. Notably, especially in terms of muscle tone, these regulations are bidirectional, namely, orexin facilitates muscle tone or inhibits it depending on the region. We consider regulation of pain as representative of sensory systems. Both the cuneiform nucleus (CNF) and pedunculopontine tegmental nucleus (PPT) are parts of the so called mesencephalic locomotor region (MLR), and nucleus pontis oralis (PnO) contains the alleged pontine inhibitory area. Abbreviations: AccSh, nucleus accumbens shell; LC, locus coeruleus; LVN, lateral vestibular nucleus; Mo5, motor trigeminal nucleus; MVMR, medioventral medullary region; PAG, periaqueductal gray matter; PH, posterior hypothalamic area; PVH, paraventricular nucleus of hypothalamus; PVT, paraventricular nucleus of thalamus; rLH, rostralateral hypothalamus; SNc, substantia nigra pars compact; SNr, substantia nigra pars reticulata.

isoamyl acetate (Julliard *et al.*, 2007) and food odour (Prud'homme *et al.*, 2009), although it is unclear whether these increases in sensory perception are related to modulation of brain reward function. Importantly, in studies in humans, it has been established that olfactory dysfunction is a feature of narcolepsy with or without cataplexy (Stiasny-Kolster *et al.*, 2007; Buskova *et al.*, 2010), and that this state could be reversed by intranasal orexin-A (Baier *et al.*, 2008).

Locomotion

The relationship between the orexin system and locomotion was highlighted initially in behavioural tests; i.e.v. administration of orexin was shown to enhance locomotor activity (Hagan *et al.*, 1999; Ida *et al.*, 1999), which involves dopamine D₁ and D₂ receptors (Nakamura *et al.*, 2000), 5-HT (Duxon *et al.*, 2001; Matsuzaki *et al.*, 2002) and central α_1 -adrenoceptors (Stone *et al.*, 2005), whereas the selective OX₁ receptor antagonist SB-334867 reversed this effect of orexin (Duxon *et al.*, 2001). Orexin-A injected into multiple structures stimulates locomotor activity, but the effect of orexin-A in the LH is independent of its feeding effect (Kotz *et al.*, 2002; Kotz, 2006). Moreover, both orexin-A and -B, injected into the nucleus accumbens shell (AccSh), potentiated the dopamine-dependent pivoting in rats (Kotani *et al.*, 2008). However, the OX₁ receptor antagonist SB-334867 decreased the orexin-A-induced spontaneous physical activity when injected into the paraventricular nucleus (PVN) (Kiwaki *et al.*, 2004), but did not have any effects when injected into the AccSh (Thorpe and Kotz, 2005). Consistent with its motor stimulating effect, an injection of orexin into the medioventral medullary alpha parts, LC (Kiyashchenko *et al.*, 2001; Mileykovskiy *et al.*, 2002), pedunculopontine

nuclei (PPN), substantia nigra pars reticulata (Takakusaki *et al.*, 2005) or trigeminal motor nucleus (Peever *et al.*, 2003) increased muscle tone, but inhibited muscle tone when injected in the gigantocellular nucleus, dorsal paragigantocellular nucleus and nucleus pontis oralis (Kiyashchenko *et al.*, 2001; Mileykovskiy *et al.*, 2002).

Recently, Zhang *et al.* (2011) demonstrated that orexin-A signalling in the rat lateral vestibular nucleus (LVN) is involved in the vestibular-mediated motor, postural control and negative geotaxis, and intriguingly, whereas microinjection of SB-334867 into the LVN usually has no effect on this condition, it makes a difference when the rat is facing a major motor challenge. These results suggest that the motor effects of orexin are independent of its function in arousal and emotion, and provide a possible mechanism for the loss of muscle tone in cataplexy attacks. Interestingly, administration of orexin-A into the paraventricular nucleus of the midline thalamus reduces distance travelled, yet enhances the grooming and freezing behaviours in animals, whereas the OX receptor antagonist SB-334867 has no effects on these variables (Li *et al.*, 2009; 2010b). Consistent with the elevated levels of activity of the orexin system during active wakefulness being associated with high muscle tone and stirring movements (Kiyashchenko *et al.*, 2002; Tortorolo *et al.*, 2003), the orexin system has been shown to be involved in the maintenance of food anticipatory activity (Akiyama *et al.*, 2004).

Cognition

Results from *in vitro* studies have shown that orexin augments excitatory activity in the prefrontal cortex (PFC) through both pre- (Fetissov *et al.*, 2004; Huang *et al.*, 2006) and post-synaptic (Song *et al.*, 2005; Xia *et al.*, 2005; 2009; Li *et al.*,

Figure 3

Effects of orexin (Hcrt) on arousal and cognition areas. This diagram summarizes the effects of orexin on nuclei involved in arousal and cognition (including learning). It should be noted that a role for the medial temporal lobe (MTL) and striatum [i.e. caudate putamen (CPu)] in these effects of orexin were suggested by a human study, in addition to the prefrontal cortex (PFC) and thalamus suggested from animal and human studies. The medial septum and diagonal band of Broca (MSDM) is included in the basal forebrain (BF); the MTL consists of the hippocampus, entorhinal cortex (EC), peri- and postrhinal cortex, subiculum, and pre- and parasubiculum (Pr-PaS). Abbreviations: CA1, Cornu Ammonis area 1; DG, dentate gyrus; DR, dorsal raphe nuclei; LC, locus coeruleus; LDT/PPT, laterodorsal tegmental nucleus/pedunculopontine tegmental nucleus; Th, thalamus; TMN, tuberomammillary nucleus; vPAG, ventral periaqueductal gray matter.

2010a; Yan *et al.*, 2012) mechanisms, which implies a potential role for orexin in cognition.

This involvement of orexin in cognition *in vivo* was first demonstrated by Lambe *et al.* (2005); they showed that an intra-PFC injection of orexin-B improved attentional processes in rats. Also i.v. injections and nasal delivery of orexin-A have been found to reduce the deleterious effects of sleep deprivation on cognitive performance in non-human primates. This effect was attributed to an increase in the activity of the dorsolateral prefrontal cortex, striatum and thalamus and an attenuation of the activation of the medial temporal lobe (Deadwyler *et al.*, 2007). Moreover, an injection of orexin-A into the rostral intralaminar thalamic nuclei has been found to promote working memory (Mair and Hembrook, 2008), whereas, administration of OX₁ receptor antagonist SB-334867 disrupts attentional performance in rats (Boschen *et al.*, 2009). More recently, it was observed that the ability of narcoleptic patients to make decisions under ambiguity conditions is impaired compared to their performance under explicit conditions (Bayard *et al.*, 2011).

More interestingly, i.c.v. injection of orexin-A has been shown to improve memory in both an active and passive avoidance paradigm (Jaeger *et al.*, 2002; Telegdy and Adamik, 2002). In contrast, i.c.v. administration of the OX₁ receptor antagonist SB-334867 attenuated taste preference learning in rats (Mediavilla *et al.*, 2011). Furthermore, antagonizing OX₁ receptors with SB-334867 in the CA1 or dentate gyrus impairs acquisition, consolidation and retrieval in the Morris water maze (Akbari *et al.*, 2006; 2007) and passive avoidance tasks (Akbari *et al.*, 2008). Further, in support of a role for orexin in memory, the spatial memory of rats with orexin- saporin lesions in the medial septum and diagonal band of Broca was impaired (Smith and Pang, 2005). Consistent with

these observations, orexin-A has been shown to activate noradrenaline-induced long-term potentiation (LTP) in the dentate gyrus (Walling *et al.*, 2004), and to modulate long-term synaptic plasticity in CA1 region in an age-dependent manner (Selbach *et al.*, 2004; 2010). However, the exact role of orexin in learning and memory is still unclear. Although there is evidence that orexin-A impairs Morris water maze performance of rats and suppresses the LTP in hippocampal CA1 neurons (Aou *et al.*, 2003), it has also been found that administration of almorexant (p.o.), a dual OX receptor antagonist, has no effect on the learning and memory of rats (Dietrich and Jenck, 2010). However, the neuroexcitatory activity of the orexin peptides is consistent with an increase in excitability of postsynaptic dendrites in hippocampal neurons and enhanced LTP and memory, but the slow dynamics and the diversity of hyperpolarizing conductances activated by OX receptors may also explain the opposite results obtained (see Figure 3).

The reward system

The LH has long been known to have a prominent role in reward. Olds and Milner (Olds and Milner, 1954; Olds, 1962) showed that rats would self-stimulate current when an electrode was placed in the lateral hypothalamic region, in close proximity to orexin neurons. This effect was thought to be mediated by the medial forebrain bundle, which contains fibres of passage to the dopaminergic mesencephalic neurons from several neighbouring nuclei. Indeed, anatomical data have shown that orexin cells project to dopaminergic neurons in the VTA (Balcita-Pedicino and Sesack, 2007), although few synapses have been observed and many of these projections are fibres of passage.

The functional role of orexin in the reward process was demonstrated by Boutrel *et al.* (2005), who showed that i.c.v. infusion of orexin-A elevated intracranial self-stimulation thresholds in rats, which suggests that it decreases brain reward function by an action different from dopamine excitation. Indeed, there is much evidence connecting orexin with the effects of opioids and corticotrophin-releasing factor (CRF). Furthermore, orexin-A has been shown to facilitate glutamatergic synapses in dopaminergic neurons in the ventral tegmental area (VTA), providing a cellular basis for its behavioural effects (Borgland *et al.*, 2006). Many other authors have now shown a direct role for orexin in the re-instatement of opioid- (Harris *et al.*, 2005), cocaine- (Aston-Jones *et al.*, 2008), alcohol- (Lawrence *et al.*, 2006) and nicotine-seeking (Plaza-Zabala *et al.*, 2010) behaviour. The orexin system may be differentially involved in stress- compared to cue-induced re-instatement of drug seeking behaviour. Interactions with non-dopaminergic systems such as CRF (see Stress section) or noradrenergic signalling may account for these neuromodulatory effects on drug-seeking behaviour following its eradication.

Also, it has been hypothesized that orexins have a role in sexual behaviour (Muschamp *et al.*, 2007; Bai *et al.*, 2009). Although the mechanisms of increased sexual drive may include the circuits involved in natural reward, there is no data directly linking orexin-induced hypersexuality and dopaminergic transmission. Detailed reviews on the role of orexin in brain reward and addiction have been recently published elsewhere (Mahler *et al.*, 2012).

Energy homeostasis

Sakurai *et al.* (1998) delineated the orexigenic effect of the peptide in his landmark paper, which was validated by subsequent studies (Yamanaka *et al.*, 1999); they showed that i.c.v. administration of pharmacological doses of orexin increases food intake, whereas administration of an antibody or OX receptor antagonist reduces food consumption in rats (Haynes *et al.*, 2000). Yamanaka *et al.* (2003a) further demonstrated in an elegant study that one possible function of the orexin system is to integrate metabolic state into locomotor activity. Thus, they showed that mice lacking orexinergic neurons do not show an increase in locomotor activity induced by starvation. Other groups have shown that orexin-induced feeding is modulated by caloric challenge (Thorpe *et al.*, 2005b). Orexinergic neurons are inhibited by glucose (Yamanaka *et al.*, 2003a; Burdakov, 2004; Burdakov and Alexopoulos, 2005), triglycerides (Chang *et al.*, 2004) and amino acids (Karnani *et al.*, 2011). Moreover, the orexigenic peptide ghrelin activates orexinergic neurons whereas leptin, a hormone from adipose tissue, inhibits orexin cells (Yamanaka *et al.*, 2003a,b). There is substantial evidence suggesting that orexinergic neurons in the LH have a prominent role in sensing the steady-state levels of physiologically relevant metabolites and integrate this information into a coherent value that is conveyed to arousal centres (Adamantidis and de Lecea, 2008b; 2009; Carter *et al.*, 2009b).

With regard to the local hypothalamic circuit that regulates feeding, orexin excites MCH neurons (van den Pol *et al.*, 2004) and inhibits ventral medial hypothalamic (VMH)

glucoreceptors to enhance feeding behaviours (Shiraishi *et al.*, 2000). Moreover, a recent study demonstrated that the area postrema and nucleus of the tractus solitarius (NTS) are necessary for orexin-mediated hyperphagia (Baird *et al.*, 2009). More recently, another elegant study suggested that orexin neurons belong to the higher-order brain neurons that regulate the feeding-related motor and autonomic end organs (Perez *et al.*, 2011). Furthermore, administration of orexin into the accumbens shell augments feeding behaviours (Thorpe and Kotz, 2005). DAMGO (a μ -opioid receptor agonist) injected into the core of the nucleus accumbens, mediated feeding behaviour by affecting OX₁ receptor signalling in the VTA (Zheng *et al.*, 2007).

In addition to a direct interaction with feeding circuits and with humoral signals affecting feeding, orexinergic neurons have a prominent regulatory role in the brain reward system, and particularly for palatable food (Thorpe *et al.*, 2005a; Borgland *et al.*, 2009; 2010). The OX₁ receptor has been shown to mediate food motivation and reward-based feeding behaviour in mice (Sharf *et al.*, 2010) and rats (Choi *et al.*, 2010).

Importantly, orexins also modulate energy homeostasis by coordinating humoral factors. Administration of orexin-A s.c. increases the blood concentration of two adiposity signals: insulin (Nowak *et al.*, 2000) and leptin (Switonska *et al.*, 2002), which may explain why orexin signalling is enhanced in obesity-resistant rats (Mavanji *et al.*, 2010). The relationship between orexin and leptin has been demonstrated at the anatomical level by Myers and colleagues (Louis *et al.*, 2010; Leininger *et al.*, 2011); they identified a population of MCH-GABA + neurons in the LH that contain leptin receptors and make dense synaptic contacts with orexin cells. The specific role of these neurons in mediating food reward and integrating limbic signals remains to be determined. Funato *et al.* (2009) showed that augmented OX₂ receptor signalling improves insulin sensitivity and protects the mouse from diet-induced obesity, probably through improving leptin sensitivity. Following this study, Shiuchi *et al.* (2009) demonstrated that administration of orexin-A into the VMH also improves insulin sensitivity and enhances feeding-associated glucose utilization in skeletal muscle by enhancing the sympathetic tone and β -adrenoceptor-mediated signalling.

All these findings suggest that orexinergic neurons maintain a proper balance between energy intake or storage and expenditure initially by monitoring the nutritional state of the body in real time. Orexins also regulate energy intake or storage and expenditure by modulating the feeding and energy homeostasis-related circuits. It has been shown that the effect of orexin on appetite requires intact arcuate nucleus activity (Moreno *et al.*, 2005), partially due to its dependence on activation of the neuropeptide Y (NPY) pathway (Yamanaka *et al.*, 2000). Also in further support of a role for orexin in the modulation of local feeding circuits, it was found that administration of orexin into the paraventricular hypothalamus, dorsomedial hypothalamus, perifornical area or LH increases food intake (Dube *et al.*, 1999; Thorpe *et al.*, 2003). Like ghrelin, orexin facilitates the pacemaker activities of NPY/AgRP neurons but inhibits the effects of the proopiomelanocortin (POMC) neurons that suppress appetite (Muroya *et al.*, 2004; Ma *et al.*, 2007).

Endocrine

During the past decade, as discussed in detail in other reviews (Ferguson and Samson, 2003; Lopez *et al.*, 2010), anatomical data have suggested that orexin plays an important role in the regulation of endocrine function, including the hypothalamic-pituitary-adrenal (HPA), hypothalamic-pituitary-gonad (HPG), hypothalamic-pituitary-thyroid (HPT) systems, growth hormone (GH) and prolactin axes.

These data have now been supported by several physiological studies as detailed below.

HPA axis. Administration of orexin-A, i.c.v., increases plasma adrenocorticotrophic hormone (ACTH), corticosterone concentrations, as well as CRF mRNA levels and fos expression in the parvocellular cells of PVN (Al-Barazani *et al.*, 2001). This orexin-induced activation of the HPA axis involves both OX receptors (Samson and Taylor, 2001; Samson *et al.*, 2002; Ferguson and Samson, 2003), and NPY-dependent (Jaszberenyi *et al.*, 2001) and NPY-independent (Moreno *et al.*, 2005) pathways. Interestingly, these responses are attenuated by pregnancy or CRF antagonists (Jaszberenyi *et al.*, 2000). Moreover, ACTH production is reduced in narcoleptic patients (Kok *et al.*, 2002).

However, orexin-A suppresses the CRF-stimulated ACTH secretion (Samson and Taylor, 2001). Moreover, orexin-A directly stimulates corticosterone secretion (Malendowicz *et al.*, 1999; 2001; Ziolkowska *et al.*, 2005), and stimulates (Kawada *et al.*, 2003), inhibits (Nanmoku *et al.*, 2000), or has no effect (Mazzocchi *et al.*, 2001) on catecholamine release from the adrenal medulla or pheochromocytoma cells. In addition, orexin also modulates the proliferation of normal adrenocortical cells or adenomatous cells (Spinazzi *et al.*, 2005a,b).

Whether orexin peptides can be produced by extrahypothalamic sources is still not known. A significant body of literature indicates peptide activity and receptor expression in peripheral organs including the adrenal gland and the gonads. However, there is still no consensus about the origin and the quality of orexin immunoreactive signals in plasma (Arihara *et al.*, 2001; Dalal *et al.*, 2001; Adam *et al.*, 2002; Higuchi *et al.*, 2002; Igarashi *et al.*, 2003; Busquets *et al.*, 2004; Baranowska *et al.*, 2005).

Taken together, the existing data suggest that the orexin-ergic system at least centrally, is an important modulator of CRF responses and, by extension, of the HPA axis, with potential implications in stress, anxiety and panic disorders.

HPG axis. Administration of orexins, i.c.v., increases LH secretion in ovariectomized (OVX) female rats in the presence of oestradiol and progesterone (Brunton and Russell, 2003), consistent with the observation from orexin-deficient narcolepsy patients exhibit diminished LH release (Kok *et al.*, 2004). However, in the absence of oestradiol or progesterone, orexins suppressed LH release in OVX rats (Pu *et al.*, 2000). Potential mechanisms for this effect may involve NPY (Kiyokawa *et al.*, 2011), CRF (Iwasa *et al.*, 2007), β -endorphin (Irahara *et al.*, 2001) and oestrogen (Furuta *et al.*, 2002). In addition to its ovarian steroid-dependent actions, orexin-A has region-dependent effects on LH release; it increases LH release when microinjected into the rostral preoptic area but reduces LH release when microinjected into the medial

preoptic area or arcuate/median eminence, an effect which can be inhibited by the selective OX₁ receptor antagonist SB-334867 (Small *et al.*, 2003).

Notably, orexins also exert their endocrine effects at the testicular level, as orexin-A directly stimulates testosterone secretion in rat testis. In contrast, expressions of key Sertoli cell genes and DNA synthesis in specific stages of the seminiferous epithelium are inhibited by orexin-A (Barreiro *et al.*, 2004; 2005). In addition, i.p. injection of an OX₁ receptor antagonist (SB-334867) and/or a selective OX₂ receptor antagonist (JNJ-10397049) decreased pro-oestrus gonadotropins and ova number, accompanied by haematological (hyperaemic and/or haemorrhagic) reaction of ovaries with more preovulatory follicles and less corpora lutea (Silveyra *et al.*, 2007). Among the peripheral actions of the orexin peptides, those reported in the gonads seem to have the strongest and most reliable responses. No reports of decreased fertility in narcoleptics have been published, but whether orexin-deficiency in narcolepsy also applies to peripheral sources is unclear.

HPT axis. Orexin-A, i.c.v., inhibits the release of hypothalamic thyrotropin-releasing hormone and subsequently reduces the plasma levels of thyrotropin (TSH). However, orexin-A failed to affect TSH release at the adenohypophysis level, and the plasma thyroid hormone levels showed no changes after peripheral or intra-PVN administration of orexin-A (Mitsuma *et al.*, 1999; Samson and Taylor, 2001; Russell *et al.*, 2002). In addition, narcoleptic patients exhibit decreased plasma TSH concentrations (Kok *et al.*, 2005) but normal plasma thyroid levels (Chabas *et al.*, 2007). In contrast to orexin-A, i.c.v. administration of orexin-B increases the plasma TSH level (Jones *et al.*, 2001). It is possible that imbalances in TSH levels are the cause of metabolic alterations and obesity in adolescent narcoleptics.

GH. In early studies, orexin-A was reported not to stimulate GH release directly (Xu *et al.*, 2002) but to enhance GH-releasing hormone (GHRH)-stimulated GH secretion (Xu *et al.*, 2002) in primary cultured ovine somatotrophs, whereas orexin-B directly increased GH secretion. Furthermore, both orexin-A (Seoane *et al.*, 2004) and orexin-B (Barb and Matteri, 2005) failed to affect the GH secretion from pituitary cells. Administration of orexin-A, i.c.v., was found to reduce the plasma GH levels (Hagan *et al.*, 1999) by inhibiting spontaneous GH secretion (Seoane *et al.*, 2004). Moreover, orexin-A stimulates somatostatin release (Russell *et al.*, 2000) and increases the somatostatin mRNA content in the hypothalamic periventricular nucleus in a GH-dependent manner (Lopez *et al.*, 2004) but selectively decreases the GHRH mRNA in PVN. In addition, orexin-A markedly blunted the GH responses to ghrelin but not GHRH (Seoane *et al.*, 2004). Finally, orexin-deficient narcoleptic patients exhibit normal rates of basal and pulsatile GH secretion (Overeem *et al.*, 2003).

Prolactin. Orexins decrease basal plasma prolactin levels (Jones *et al.*, 2001), and reduce the domperidone-induced plasma prolactin concentrations (Russell *et al.*, 2000), probably through a mechanism involving NPY (Hsueh *et al.*, 2002). In addition, orexin-A restores the fasting-induced abo-

lition of prolactin and LH surges, and anti-orexin-A antisera also abolish these surges in normally fed rats (Kohsaka *et al.*, 2001). Interestingly, the study on the pituitary explants showed that the regulation of prolactin secretion by orexin-A is day-length dependent, namely, orexin-A increases prolactin secretion during the long days (May) but decreases it during the short days (December) (Molik *et al.*, 2008). However, a recent clinical study showed that prolactin secretion is no different in narcolepsy patients than in matched controls (Donjacour *et al.*, 2011), consistent with a lack of effect of both orexin-A and orexin-B on prolactin secretion at the pituitary level (Russell *et al.*, 2000; Russell *et al.*, 2001; Samson and Taylor, 2001).

Stress

The terminology of 'stress' means a subjective state perceiving or anticipating the adverse disturbances in surroundings, which further activates various stress mediators to elicit proper responses (Joels, 2009). The role of the orexinergic system in stress responses has been well established on the basis of three kinds of evidence. Firstly, many stressors, including immobilization, footshock, cold exposure, conditioned fear, food and neonatal maternal deprivation are able to activate the orexinergic system (Ida *et al.*, 2000; Sakamoto *et al.*, 2004; Winsky-Sommerer *et al.*, 2004; 2005; Furlong *et al.*, 2009) (Horvath and Gao, 2005). Secondly, some stress-induced responses, such as stress-induced analgesia (Xie *et al.*, 2008), footshock-induced re-instatement of cocaine seeking (Boutrel *et al.*, 2005; Boutrel and de Lecea, 2008; Boutrel *et al.*, 2009) as well as stress-induced ACTH and cardiovascular responses (Samson and Taylor, 2001; Kayaba *et al.*, 2003; Chang *et al.*, 2007), induce activation of the orexin system. It is noteworthy that orexin-A is not involved in stress-induced thermogenesis (Zhang *et al.*, 2010) or cardiovascular responses to cold exposure (Furlong *et al.*, 2009), even though it is able to inhibit stress-induced delayed increase in the amount of REM sleep (Rachalski *et al.*, 2009). Finally, activation of orexinergic neurons results in some stress-like effects. As discussed earlier, orexin can activate the HPA axis including CRF, ACTH and corticosterone, stimulate stress-related behaviours like grooming and chewing of inedible material, and enhance the activation of the monoamine system in a stress-like manner (Berridge *et al.*, 2010).

A link between orexin and stress-related pathologies, such as panic disorder, has recently been established (Johnson *et al.*, 2010; Lungwitz *et al.*, 2012). Panic attacks involve activation of the HPA axis and the autonomic system. Intrahypothalamic administration of an RNAi to orexin or an OX₁ receptor antagonist has been shown to block these panic responses in rats injected with sodium lactate, and elevated levels of orexin-A have been detected in humans with panic disorder (Johnson *et al.*, 2010).

Visceral functions

The orexin system has also been found to effect visceral functions, in addition to its roles in energy homeostasis and endocrine function, mentioned previously.

Circulatory system. Orexin-deficient mice exhibit lower arterial blood pressure, heart rate and sympathetic tone (Kayaba

et al., 2003). Furthermore, i.c.v., intracisternally or intrathecally applied orexin increases the mean arterial pressure (MAP), heart rate (HR), renal sympathetic nerve activity and plasma catecholamine or vasopressin levels (Samson *et al.*, 1999; 2005; Shirasaka *et al.*, 1999; 2002; Matsumura *et al.*, 2001; Hirota *et al.*, 2003), effects that are blocked or attenuated by the OX₁ receptor antagonist SB-334867 (Hirota *et al.*, 2003; Shahid *et al.*, 2011). However, i.v. injections of orexin-A have no effect on sympathetic activity (Matsumura *et al.*, 2001), suggesting that the cardiac effects of orexin are mediated centrally. Consistently, microinjections of orexin-A into the rostral ventrolateral medulla (Huang *et al.*, 2010) or rostral ventromedial medulla (Ciriello and de Oliveira, 2003) elicit cardiovascular excitatory responses through the activation of both OX₁ and OX₂ receptors (Huang *et al.*, 2010).

However, orexin-A signalling in the nucleus ambiguus (NA) (de Oliveira and Ciriello, 2003) and subfornical organ (Smith *et al.*, 2007) has been shown to produce bradycardia responses, which are, respectively, mediated by an elevation of vagal excitation and a reduction of sympathetic tone. In contrast, it has also been found that orexin-A enhances the inhibitory input and attenuates excitatory synapses to vagal neurons in the NA (Dergacheva *et al.*, 2005). Moreover, the cardiac effects of orexin in the NTS are both dose- and site-dependent, as orexin increases MAP and HR at higher doses (>20 pmol) but reduces these variables at a lower dose (5 pmol). Furthermore, microinjections of orexin into the caudal lateral and medial subnuclei of the NTS decrease both the MAP and HR (de Oliveira *et al.*, 2003b), whereas pressor and tachycardiac effects were obtained when orexin was injected into the commissural nucleus of NTS (Smith *et al.*, 2002).

Respiratory effects. Several studies with preproorexin-KO and orexinergic neuron-ablated mice have demonstrated the essential role orexin plays in the hypercapnic chemoreflex response, as well as in phrenic and ventilatory long-term facilitation (Deng *et al.*, 2007; Nakamura *et al.*, 2007; Terada *et al.*, 2008). Also, pharmacological experiments have shown that i.c.v., intracisternal or intrathecal administration of orexin has the ability to elevate respiratory frequency, tidal volume and minute ventilation (Shahid *et al.*, 2011). Furthermore, orexin signalling on OX₁ receptors in the retrotrapezoid nucleus contributes to the control of the hypercapnic chemoreflex (Dias *et al.*, 2009). In addition, when applied to the pre-Botzinger region and phrenic nuclei, orexin augments the phrenic nerve discharge and, subsequently, the electromyographic activity of the diaphragm (Liu *et al.*, 2010). Moreover, injection of orexin-B into pontine Kölliker-Fuse nucleus results in an increase in respiratory frequency and facilitation of upper airway patency (Dutschmann *et al.*, 2007). In parallel, it may be worth noting that orexinergic neurons are strongly inhibited by anaesthetics and orexin-KO mice show delayed emergence from isoflurane anaesthesia (Kelz *et al.*, 2008). However, ambient levels of H⁺ and CO₂ can significantly enhance the activation of orexinergic neurons (Williams *et al.*, 2007; Williams and Burdakov, 2008). Unlike in mice, chemoresponsiveness in humans is independent of OX₁ receptors, as the different ventilatory responses to hypoxia observed in humans with narcolepsy-cataplexy have

been associated with the HLA-DQB1*0602 allele that segregates with narcolepsy, but not an orexin deficiency (Han, 2012). Therefore, in humans ventilatory responses to hypoxia may be mediated by other factors or immune components independent of orexin.

It has been suggested that orexinergic neurons are involved in sleep apnoea syndrome, as patients show increased plasma levels of orexin-A (Igarashi *et al.*, 2003; Busquets *et al.*, 2004). Hypercapnia and associated reflexes may increase the activity of orexinergic neurons during sleep, facilitating microarousals and a cascade of sympathetic activity that results in elevated blood pressure during the night. Thus, OX receptor antagonists could be used to prevent these peaks of blood pressure in mild sleep apnoea.

Regulation of digestive activity. Early work showed that orexin immunoreactivity is present in intestinal tissue (Kirchgessner and Liu, 1999). Intracisternal or intraventricular hypothalamus, but not i.p., injections of orexin-A stimulate gastric acid secretion by activating the vagal system through OX₁ receptors (Takahashi *et al.*, 1999; Yamada *et al.*, 2005; Eliassi *et al.*, 2009; Kermani and Eliassi, 2012). Moreover, activation of OX₁ receptors in the dorsal motor nucleus of the vagus results in facilitation of vagal pancreatic efferent nerve activities (Wu *et al.*, 2004), stimulating pancreatic exocrine secretion (Miyasaka *et al.*, 2002). Administration of orexin-A, i.a., increases duodenal secretion in normal fed but not in fasted animals, by an effect that is independent of cholinergic pathways (Flemstrom *et al.*, 2003; Bengtsson *et al.*, 2007). In addition, orexin-A can modify gastrointestinal motility, including gastric emptying, gastric interdigestive motility (Naslund *et al.*, 2002; Ehrstrom *et al.*, 2005a,b; Bulbul *et al.*, 2010), and enteric peristalsis (Satoh *et al.*, 2006), as well as colonic motility (Kirchgessner and Liu, 1999; Nozu *et al.*, 2011). It is noteworthy that orexin exerts region-specific effects on gastric contractility and relaxation both at the central and peripheral levels, by mechanisms involving ACh and NO respectively (Kobashi *et al.*, 2002; Krowicki *et al.*, 2002; Baccari *et al.*, 2009; Baccari, 2010). Furthermore, orexin-A shows gastro-protective effects against stress-induced (Brzozowski *et al.*, 2008), ischaemia-reperfusion-induced (Bulbul *et al.*, 2008) or ethanol-induced (Yamada *et al.*, 2007) gastric damage.

Urinary activity. The presence of orexin-A and its receptors has been shown in human kidneys and urine (Takahashi *et al.*, 2006), as well as in the bovine urethroprostatic complex (Russo *et al.*, 2008). These findings are supported by results from physiological studies, which demonstrated that orexin-A is involved in the pelvic-urethral reflex (Peng *et al.*, 2008) and the micturition reflex (Kobayashi *et al.*, 2009).

Overall perspective

The remarkable pleiotropic role of a relatively small neuronal system such as the one formed by orexin cells can be explained in the context of an integrating system that controls some key features of a homeostatic output. Indeed, it is hard to imagine a central role in such diverse functions as endocrine, pain or respiration for such a relatively recent

peptide, evolutionary speaking. The ubiquitous distribution of the axonal processes of orexin, the phasic nature of its activity (possibly superimposed on a circadianly regulated endocrine release), and the very slow action on at least some postsynaptic sites suggests it has a broad modulatory role. Orexinergic neurons may thus integrate activity from diverse inputs from limbic structures over windows of 1–10 s and, depending on the state of membrane depolarization, may fire phasically to induce postsynaptic depolarizations in many structures. These depolarizations may be subthreshold or elicit action potentials, depending on the state of depolarization of their postsynaptic targets. Failure to integrate critical information at precise times of awakening causes the behavioural instability associated with narcolepsy/cataplexy. As reviewed here, the orexins are also involved in many peripheral actions, including endocrine, respiration, cardiovascular and gastrointestinal effects, but the mechanisms of such effects are still poorly understood. As drugs that affect orexin signalling enter the market, more attention will be devoted to the myriad possible functions of these hormones. Moreover, these advances may also lead to the development of small molecule orexin ligands that could serve as an effective treatment for narcolepsy/cataplexy and other sleep disorders.

Conflict of interest

None.

References

- Adam JA, Menheere PP, van Dielen FM, Soeters PB, Buurman WA, Greve JW (2002). Decreased plasma orexin-A levels in obese individuals. *Int J Obes Relat Metab Disord* 26: 274–276.
- Adamantidis A, de Lecea L (2008a). Physiological arousal: a role for hypothalamic systems. *Cell Mol Life Sci* 65: 1475–1488.
- Adamantidis A, de Lecea L (2008b). Sleep and metabolism: shared circuits, new connections. *Trends Endocrinol Metab* 19: 362–370.
- Adamantidis A, de Lecea L (2009). The hypocretins as sensors for metabolism and arousal. *J Physiol* 587 (Pt 1): 33–40.
- Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, de Lecea L (2007). Neural substrates of awakening probed with optogenetic control of hypocretin neurons. *Nature* 450: 420–424.
- Akbari E, Naghdi N, Motamedi F (2006). Functional inactivation of orexin 1 receptors in CA1 region impairs acquisition, consolidation and retrieval in Morris water maze task. *Behav Brain Res* 173: 47–52.
- Akbari E, Naghdi N, Motamedi F (2007). The selective orexin 1 receptor antagonist SB-334867-A impairs acquisition and consolidation but not retrieval of spatial memory in Morris water maze. *Peptides* 28: 650–656.
- Akbari E, Motamedi F, Naghdi N, Noorbakhshnia M (2008). The effect of antagonization of orexin 1 receptors in CA(1) and dentate gyrus regions on memory processing in passive avoidance task. *Behav Brain Res* 187: 172–177.
- Akiyama M, Yuasa T, Hayasaka N, Horikawa K, Sakurai T, Shibata S (2004). Reduced food anticipatory activity in genetically orexin (hypocretin) neuron-ablated mice. *Eur J Neurosci* 20: 3054–3062.

- Al-Barazanjy KA, Wilson S, Baker J, Jessop DS, Harbuz MS (2001). Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats. *J Neuroendocrinol* 13: 421–424.
- Alexander SPH *et al.* (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. *Br J Pharmacol* 170: 1449–1867.
- Anaclet C, Parmentier R, Ouk K, Guidon G, Buda C, Sastre JP *et al.* (2009). Orexin/hypocretin and histamine: distinct roles in the control of wakefulness demonstrated using knock-out mouse models. *J Neurosci* 29: 14423–14438.
- Aou S, Li XL, Li AJ, Oomura Y, Shiraishi T, Sasaki K *et al.* (2003). Orexin-A (hypocretin-1) impairs Morris water maze performance and CA1-Schaffer collateral long-term potentiation in rats. *Neuroscience* 119: 1221–1228.
- Appelbaum L, Wang G, Yokogawa T, Skariah GM, Smith SJ, Mourrain P *et al.* (2010). Circadian and homeostatic regulation of structural synaptic plasticity in hypocretin neurons. *Neuron* 68: 87–98.
- Arihara Z, Takahashi K, Murakami O, Totsune K, Sone M, Satoh F *et al.* (2001). Immunoreactive orexin-A in human plasma. *Peptides* 22: 139–142.
- Aston-Jones G, Smith RJ, Moorman DE, Richardson KA (2008). Role of lateral hypothalamic orexin neurons in reward processing and addiction. *Neuropharmacology* 56 (Suppl. 1): 112–121.
- Baccari MC (2010). Orexins and gastrointestinal functions. *Curr Protein Pept Sci* 11: 148–155.
- Baccari MC, Bani D, Calamai F (2009). Evidence for a modulatory role of orexin A on the nitergic neurotransmission in the mouse gastric fundus. *Regul Pept* 154: 54–59.
- Bai YJ, Li YH, Zheng XG, Han J, Yang XY, Sui N (2009). Orexin A attenuates unconditioned sexual motivation in male rats. *Pharmacol Biochem Behav* 91: 581–589.
- Baier PC, Weinhold SL, Huth V, Gottwald B, Ferstl R, Hinze-Selch D (2008). Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal orexin A (hypocretin-1). *Brain* 131 (Pt 10): 2734–2741.
- Baird JP, Choe A, Loveland JL, Beck J, Mahoney CE, Lord JS *et al.* (2009). Orexin-A hyperphagia: hindbrain participation in consummatory feeding responses. *Endocrinology* 150: 1202–1216.
- Balcita-Pedicino JJ, Sesack SR (2007). Orexin axons in the rat ventral tegmental area synapse infrequently onto dopamine and gamma-aminobutyric acid neurons. *J Comp Neurol* 503: 668–684.
- Baranowska B, Wolinska-Witort E, Martynska M, Chmielowska M, Baranowska-Bik A (2005). Plasma orexin A, orexin B, leptin, neuropeptide Y (NPY) and insulin in obese women. *Neuro Endocrinol Lett* 26: 293–296.
- Barb CR, Matteri RL (2005). Orexin-B modulates luteinizing hormone and growth hormone secretion from porcine pituitary cells in culture. *Domest Anim Endocrinol* 28: 331–337.
- Barreiro ML, Pineda R, Navarro VM, Lopez M, Suominen JS, Pinilla L *et al.* (2004). Orexin 1 receptor messenger ribonucleic acid expression and stimulation of testosterone secretion by orexin-A in rat testis. *Endocrinology* 145: 2297–2306.
- Barreiro ML, Pineda R, Gaytan F, Archanco M, Burrell MA, Castellano JM *et al.* (2005). Pattern of orexin expression and direct biological actions of orexin-A in rat testis. *Endocrinology* 146: 5164–5175.
- Bartsch T, Levy MJ, Knight YE, Goadsby PJ (2004). Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. *Pain* 109: 367–378.
- Bayard S, Abril B, Yu H, Scholz S, Carlander B, Dauvilliers Y (2011). Decision making in narcolepsy with cataplexy. *Sleep* 34: 99–104.
- Bayer L, Eggermann E, Serafin M, Saint-Mieux B, Machard D, Jones B *et al.* (2001). Orexins (hypocretins) directly excite tuberomammillary neurons. *Eur J Neurosci* 14: 1571–1575.
- Bayer L, Eggermann E, Serafin M, Grivel J, Machard D, Muhlethaler M *et al.* (2005). Opposite effects of noradrenaline and acetylcholine upon hypocretin/orexin versus melanin concentrating hormone neurons in rat hypothalamic slices. *Neuroscience* 130: 807–811.
- Bengtsson MW, Makela K, Sjoblom M, Uotila S, Akerman KE, Herzig KH *et al.* (2007). Food-induced expression of orexin receptors in rat duodenal mucosa regulates the bicarbonate secretory response to orexin-A. *Am J Physiol Gastrointest Liver Physiol* 293: G501–G509.
- Berridge CW, Espana RA, Vittoz NM (2010). Hypocretin/orexin in arousal and stress. *Brain Res* 1314: 91–102.
- Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M *et al.* (2001). Orexin-A, an hypothalamic peptide with analgesic properties. *Pain* 92: 81–90.
- Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A (2006). Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. *Neuron* 49: 589–601.
- Borgland SL, Chang SJ, Bowers MS, Thompson JL, Vittoz N, Floresco SB *et al.* (2009). Orexin A/hypocretin-1 selectively promotes motivation for positive reinforcers. *J Neurosci* 29: 11215–11225.
- Borgland SL, Ungless MA, Bonci A (2010). Convergent actions of orexin/hypocretin and CRF on dopamine neurons: emerging players in addiction. *Brain Res* 1314: 139–144.
- Boschen KE, Fadel JR, Burk JA (2009). Systemic and intrabasalis administration of the orexin-1 receptor antagonist, SB-334867, disrupts attentional performance in rats. *Psychopharmacology (Berl)* 206: 205–213.
- Bourgin P, Huitron-Resendiz S, Spier AD, Fabre V, Morte B, Criado JR *et al.* (2000). Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. *J Neurosci* 20: 7760–7765.
- Boutrel B, de Lecea L (2008). Addiction and arousal: the hypocretin connection. *Physiol Behav* 93: 947–951.
- Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF *et al.* (2005). Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci U S A* 102: 19168–19173.
- Boutrel B, Cannella N, de Lecea L (2009). The role of hypocretin in driving arousal and goal-oriented behaviors. *Brain Res* 1314: 103–111.
- Brisbare-Roch C, Dingemans J, Koberstein R, Hoeber P, Aissaoui H, Flores S *et al.* (2007). Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nat Med* 13: 150–155.
- Brunton PJ, Russell JA (2003). Hypothalamic-pituitary-adrenal responses to centrally administered orexin-A are suppressed in pregnant rats. *J Neuroendocrinol* 15: 633–637.
- Brzozowski T, Konturek PC, Sliwowski Z, Drozdowicz D, Burnat G, Pajdo R *et al.* (2008). Gastroprotective action of orexin-A against

- stress-induced gastric damage is mediated by endogenous prostaglandins, sensory afferent neuropeptides and nitric oxide. *Regul Pept* 148: 6–20.
- Bulbul M, Tan R, Gemici B, Ongut G, Izgut-Uysal VN (2008). Effect of orexin-a on ischemia-reperfusion-induced gastric damage in rats. *J Gastroenterol* 43: 202–207.
- Bulbul M, Babygirija R, Ludwig K, Takahashi T (2010). Central orexin-A increases gastric motility in rats. *Peptides* 31: 2118–2122.
- Burdakov D (2004). Electrical signaling in central orexin/hypocretin circuits: tuning arousal and appetite to fit the environment. *Neuroscientist* 10: 286–291.
- Burdakov D, Alexopoulos H (2005). Metabolic state signalling through central hypocretin/orexin neurons. *J Cell Mol Med* 9: 795–803.
- Buskova J, Klaschka J, Sonka K, Nevsimalova S (2010). Olfactory dysfunction in narcolepsy with and without cataplexy. *Sleep Med* 11: 558–561.
- Busquets X, Barbe F, Barcelo A, de la Pena M, Sigriz N, Mayoralas LR *et al.* (2004). Decreased plasma levels of orexin-A in sleep apnea. *Respiration* 71: 575–579.
- Caillol M, Aioun J, Baly C, Persuy MA, Salesse R (2003). Localization of orexins and their receptors in the rat olfactory system: possible modulation of olfactory perception by a neuropeptide synthesized centrally or locally. *Brain Res* 960: 48–61.
- Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, de Lecea L (2009a). Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. *J Neurosci* 29: 10939–10949.
- Carter ME, Borg JS, de Lecea L (2009b). The brain hypocretins and their receptors: mediators of allostatic arousal. *Curr Opin Pharmacol* 9: 39–45.
- Carter ME, Brill J, Bonnavion P, Huguenard JR, Huerta R, de Lecea L (2012). Mechanism for Hypocretin-mediated sleep-to-wake transitions. *Proc Natl Acad Sci U S A* 109: E2635–E2644.
- Chabas D, Foulon C, Gonzalez J, Nasr M, Lyon-Caen O, Willer JC *et al.* (2007). Eating disorder and metabolism in narcoleptic patients. *Sleep* 30: 1267–1273.
- Chang GQ, Karatayev O, Davydova Z, Leibowitz SF (2004). Circulating triglycerides impact on orexigenic peptides and neuronal activity in hypothalamus. *Endocrinology* 145: 3904–3912.
- Chang H, Saito T, Ohiwa N, Tateoka M, Deocaris CC, Fujikawa T *et al.* (2007). Inhibitory effects of an orexin-2 receptor antagonist on orexin A- and stress-induced ACTH responses in conscious rats. *Neurosci Res* 57: 462–466.
- Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C *et al.* (1999). Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* 98: 437–451.
- Choi DL, Davis JF, Fitzgerald ME, Benoit SC (2010). The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. *Neuroscience* 167: 11–20.
- Chou TC, Lee CE, Lu J, Elmquist JK, Hara J, Willie JT *et al.* (2001). Orexin (hypocretin) neurons contain dynorphin. *J Neurosci* 21: RC168.
- Ciriello J, de Oliveira CV (2003). Cardiac effects of hypocretin-1 in nucleus ambiguus. *Am J Physiol Regul Integr Comp Physiol* 284: R1611–R1620.
- Crocker A, Espana RA, Papadopoulou M, Saper CB, Faraco J, Sakurai T *et al.* (2005). Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. *Neurology* 65: 1184–1188.
- Dalal MA, Schuld A, Haack M, Uhr M, Geisler P, Eisenhr I *et al.* (2001). Normal plasma levels of orexin A (hypocretin-1) in narcoleptic patients. *Neurology* 56: 1749–1751.
- Dauvilliers Y, Bayard S, Shneerson JM, Plazzi G, Myers AJ, Garcia-Borreguero D (2011). High pain frequency in narcolepsy with cataplexy. *Sleep Med* 12: 572–577.
- Deadwyler SA, Porrino L, Siegel JM, Hampson RE (2007). Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. *J Neurosci* 27: 14239–14247.
- Deboer T, Overeem S, Visser NA, Duindam H, Frolich M, Lammers GJ *et al.* (2004). Convergence of circadian and sleep regulatory mechanisms on hypocretin-1. *Neuroscience* 129: 727–732.
- Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007). Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. *J Appl Physiol* 103: 1772–1779.
- Dergacheva O, Wang X, Huang ZG, Bouairi E, Stephens C, Gorini C *et al.* (2005). Hypocretin 1 (orexin A) facilitates inhibitory and diminishes excitatory synaptic pathways to cardiac vagal neurons in the nucleus ambiguus. *J Pharmacol Exp Ther* 314: 1322–1327.
- Deurveilher S, Semba K (2005). Indirect projections from the suprachiasmatic nucleus to major arousal-promoting cell groups in rat: implications for the circadian control of behavioural state. *Neuroscience* 130: 165–183.
- Dias MB, Li A, Nattie EE (2009). Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. *J Physiol* 587 (Pt 9): 2059–2067.
- Dietrich H, Jenck F (2010). Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. *Psychopharmacology (Berl)* 212: 145–154.
- Donjacour CE, Aziz NA, Roelfsema F, Frolich M, Overeem S, Lammers GJ *et al.* (2011). Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. *Am J Physiol Endocrinol Metab* 300: E1069–E1075.
- Dube MG, Kalra SP, Kalra PS (1999). Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. *Brain Res* 842: 473–477.
- Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW *et al.* (2009). Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. *J Pharmacol Exp Ther* 330: 142–151.
- Dutschmann M, Kron M, Morschel M, Gestreau C (2007). Activation of Orexin B receptors in the pontine Kolliker-Fuse nucleus modulates pre-inspiratory hypoglossal motor activity in rat. *Respir Physiol Neurobiol* 159: 232–235.
- Duxon MS, Stretton J, Starr K, Jones DN, Holland V, Riley G *et al.* (2001). Evidence that orexin-A-evoked grooming in the rat is mediated by orexin-1 (OX1) receptors, with downstream 5-HT2C receptor involvement. *Psychopharmacology (Berl)* 153: 203–209.
- Ehrstrom M, Gustafsson T, Finn A, Kirchgesner A, Gryback P, Jacobsson H *et al.* (2005a). Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas in man. *J Clin Endocrinol Metab* 90: 2370–2377.
- Ehrstrom M, Levin F, Kirchgesner AL, Schmidt PT, Hilsted LM, Gryback P *et al.* (2005b). Stimulatory effect of endogenous orexin A on gastric emptying and acid secretion independent of gastrin. *Regul Pept* 132: 9–16.

- Eliassi A, Nazari M, Naghdi N (2009). Role of the ventromedial hypothalamic orexin-1 receptors in regulation of gastric Acid secretion in conscious rats. *J Neuroendocrinol* 21: 177–182.
- Eriksson KS, Sergeeva O, Brown RE, Haas HL (2001). Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. *J Neurosci* 21: 9273–9279.
- Espana RA, Baldo BA, Kelley AE, Berridge CW (2001). Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. *Neuroscience* 106: 699–715.
- Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M *et al.* (2001). Fos expression in orexin neurons varies with behavioral state. *J Neurosci* 21: 1656–1662.
- Ferguson AV, Samson WK (2003). The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. *Front Neuroendocrinol* 24: 141–150.
- Fetissov SO, Huang P, Zhang Q, Mimura J, Fujii-Kuriyama Y, Rannug A *et al.* (2004). Expression of hypothalamic neuropeptides after acute TCDD treatment and distribution of Ah receptor repressor. *Regul Pept* 119: 113–124.
- Flemstrom G, Sjoblom M, Jedstedt G, Akerman KE (2003). Short fasting dramatically decreases rat duodenal secretory responsiveness to orexin A but not to VIP or melatonin. *Am J Physiol Gastrointest Liver Physiol* 285: G1091–G1096.
- Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S (2001). Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. *Neuroreport* 12: 993–997.
- Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T *et al.* (2009). Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. *Cell Metab* 9: 64–76.
- Furlong TM, Vianna DM, Liu L, Carrive P (2009). Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. *Eur J Neurosci* 30: 1603–1614.
- Furuta M, Funabashi T, Kimura F (2002). Suppressive action of orexin A on pulsatile luteinizing hormone secretion is potentiated by a low dose of estrogen in ovariectomized rats. *Neuroendocrinology* 75: 151–157.
- Gautvik KM, de Lecea L, Gautvik VT, Danielson PE, Tranque P, Dopazo A *et al.* (1996). Overview of the most prevalent hypothalamus-specific mRNAs, as identified by directional tag PCR subtraction. *Proc Natl Acad Sci U S A* 93: 8733–8738.
- Gerashchenko D, Horvath TL, Xie XS (2011). Direct inhibition of hypocretin/orexin neurons in the lateral hypothalamus by nociceptin/orphanin FQ blocks stress-induced analgesia in rats. *Neuropharmacology* 60: 543–549.
- Gorojankina T, Grebert D, Salesse R, Tanfin Z, Caillol M (2007). Study of orexins signal transduction pathways in rat olfactory mucosa and in olfactory sensory neurons-derived cell line Odora: multiple orexin signalling pathways. *Regul Pept* 141: 73–85.
- Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M *et al.* (2011). Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. *PLoS ONE* 6: e16406.
- Grivel J, Cvetkovic V, Bayer L, Machard D, Tobler I, Muhlethaler M *et al.* (2005). The wake-promoting hypocretin/orexin neurons change their response to noradrenaline after sleep deprivation. *J Neurosci* 25: 4127–4130.
- Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM *et al.* (2004). Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. *Neuropharmacology* 46: 133–149.
- Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S *et al.* (1999). Orexin A activates locus coeruleus cell firing and increases arousal in the rat. *Proc Natl Acad Sci U S A* 96: 10911–10916.
- Han F (2012). Respiratory regulation in narcolepsy. *Sleep Breath* 16: 241–245.
- Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM *et al.* (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. *Neuron* 30: 345–354.
- Harris GC, Wimmer M, Aston-Jones G (2005). A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437: 556–559.
- Hassani OK, Lee MG, Jones BE (2009). Melanin-concentrating hormone neurons discharge in a reciprocal manner to orexin neurons across the sleep-wake cycle. *Proc Natl Acad Sci U S A* 106: 2418–2422.
- Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA *et al.* (2000). A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. *Regul Pept* 96: 45–51.
- Herring WJ, Snyder E, Budd K, Hutzelmann J, Snively D, Liu K *et al.* (2012). Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. *Neurology* 79: 2265–2274.
- Higuchi S, Usui A, Murasaki M, Matsushita S, Nishioka N, Yoshino A *et al.* (2002). Plasma orexin-A is lower in patients with narcolepsy. *Neurosci Lett* 318: 61–64.
- Hirota K, Kushikata T, Kudo M, Kudo T, Smart D, Matsuki A (2003). Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats. *Brain Res* 981: 143–150.
- Hondo M, Nagai K, Ohno K, Kisanuki Y, Willie JT, Watanabe T *et al.* (2010). Histamine-1 receptor is not required as a downstream effector of orexin-2 receptor in maintenance of basal sleep/wake states. *Acta Physiol* 198: 287–294.
- Horvath TL, Gao XB (2005). Input organization and plasticity of hypocretin neurons: possible clues to obesity's association with insomnia. *Cell Metab* 1: 279–286.
- Hsueh YC, Cheng SM, Pan JT (2002). Fasting stimulates tuberoinfundibular dopaminergic neuronal activity and inhibits prolactin secretion in oestrogen-primed ovariectomized rats: involvement of orexin A and neuropeptide Y. *J Neuroendocrinol* 14: 745–752.
- Huang H, Ghosh P, van den Pol AN (2006). Prefrontal cortex-projecting glutamatergic thalamic paraventricular nucleus-excited by hypocretin: a feedforward circuit that may enhance cognitive arousal. *J Neurophysiol* 95: 1656–1668.
- Huang SC, Dai YW, Lee YH, Chiou LC, Hwang LL (2010). Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors. *J Pharmacol Exp Ther* 334: 522–529.
- Huang ZL, Qu WM, Li WD, Mochizuki T, Eguchi N, Watanabe T *et al.* (2001). Arousal effect of orexin A depends on activation of the histaminergic system. *Proc Natl Acad Sci U S A* 98: 9965–9970.
- Ida T, Nakahara K, Katayama T, Murakami N, Nakazato M (1999). Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. *Brain Res* 821: 526–529.
- Ida T, Nakahara K, Murakami T, Hanada R, Nakazato M, Murakami N (2000). Possible involvement of orexin in the stress reaction in rats. *Biochem Biophys Res Commun* 270: 318–323.

- Igarashi N, Tatsumi K, Nakamura A, Sakao S, Takiguchi Y, Nishikawa T *et al.* (2003). Plasma orexin-A levels in obstructive sleep apnea-hypopnea syndrome. *Chest* 124: 1381–1385.
- Irahara M, Tamura T, Matuzaki T, Saito S, Yasui T, Yamano S *et al.* (2001). Orexin-A suppresses the pulsatile secretion of luteinizing hormone via beta-endorphin. *Biochem Biophys Res Commun* 281: 232–236.
- Iwasa T, Matsuzaki T, Kiyokawa M, Shimizu F, Minakuchi M, Kuwahara A *et al.* (2007). The type 2 corticotrophin-releasing hormone receptor mediates orexin A-induced luteinising hormone suppression in ovariectomised rats. *J Neuroendocrinol* 19: 732–738.
- Jaeger LB, Farr SA, Banks WA, Morley JE (2002). Effects of orexin-A on memory processing. *Peptides* 23: 1683–1688.
- Jaszberenyi M, Bujdoso E, Pataki I, Telegdy G (2000). Effects of orexins on the hypothalamic-pituitary-adrenal system. *J Neuroendocrinol* 12: 1174–1178.
- Jaszberenyi M, Bujdoso E, Telegdy G (2001). The role of neuropeptide y in orexin-induced hypothalamic-pituitary-adrenal activation. *J Neuroendocrinol* 13: 438–441.
- Joels M (2009). Stress, the hippocampus, and epilepsy. *Epilepsia* 50: 586–597.
- Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S *et al.* (2010). A key role for orexin in panic anxiety. *Nat Med* 16: 111–115.
- Jones DN, Gartlon J, Parker F, Taylor SG, Routledge C, Hemmati P *et al.* (2001). Effects of centrally administered orexin-B and orexin-A: a role for orexin-1 receptors in orexin-B-induced hyperactivity. *Psychopharmacology (Berl)* 153: 210–218.
- Julliard AK, Chaput MA, Apfelbaum A, Aime P, Mahfouz M, Duchamp-Viret P (2007). Changes in rat olfactory detection performance induced by orexin and leptin mimicking fasting and satiation. *Behav Brain Res* 183: 123–129.
- Kalogiannis M, Grupke SL, Potter PE, Edwards JG, Chemelli RM, Kisanuki YY *et al.* (2010). Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons. *Eur J Neurosci* 32: 130–142.
- Karnani MM, Apergis-Schoute J, Adamantidis A, Jensen LT, de Lecea L, Fugger L *et al.* (2011). Activation of central orexin/hypocretin neurons by dietary amino acids. *Neuron* 72: 616–629.
- Kaur S, Thankachan S, Begum S, Liu M, Blanco-Centurion C, Shiromani PJ (2009). Hypocretin-2 saporin lesions of the ventrolateral periaqueductal gray (vlPAG) increase REM sleep in hypocretin knockout mice. *PLoS ONE* 4: e6346.
- Kawada Y, Ueno S, Asayama K, Tsutsui M, Utsunomiya K, Toyohira Y *et al.* (2003). Stimulation of catecholamine synthesis by orexin-A in bovine adrenal medullary cells through orexin receptor 1. *Biochem Pharmacol* 66: 141–147.
- Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I *et al.* (2003). Attenuated defense response and low basal blood pressure in orexin knockout mice. *Am J Physiol Regul Integr Comp Physiol* 285: R581–R593.
- Kelz MB, Sun Y, Chen J, Cheng Meng Q, Moore JT, Veasey SC *et al.* (2008). An essential role for orexins in emergence from general anesthesia. *Proc Natl Acad Sci U S A* 105: 1309–1314.
- Kermani M, Eliassi A (2012). Gastric acid secretion induced by paraventricular nucleus microinjection of orexin A is mediated through activation of neuropeptide Yergic system. *Neuroscience* 226: 81–88.
- Kirchgessner AL, Liu M (1999). Orexin synthesis and response in the gut. *Neuron* 24: 941–951.
- Kiwaki K, Kotz CM, Wang C, Lanningham-Foster L, Levine JA (2004). Orexin A (hypocretin 1) injected into hypothalamic paraventricular nucleus and spontaneous physical activity in rats. *Am J Physiol Endocrinol Metab* 286: E551–E559.
- Kiyashchenko LI, Mileykovskiy BY, Lai YY, Siegel JM (2001). Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. *J Neurophysiol* 85: 2008–2016.
- Kiyashchenko LI, Mileykovskiy BY, Maidment N, Lam HA, Wu MF, John J *et al.* (2002). Release of hypocretin (orexin) during waking and sleep states. *J Neurosci* 22: 5282–5286.
- Kiyokawa M, Matsuzaki T, Iwasa T, Ogata R, Murakami M, Kinouchi R *et al.* (2011). Neuropeptide Y mediates orexin A-mediated suppression of pulsatile gonadotropin-releasing hormone secretion in ovariectomized rats. *J Med Invest* 58: 11–18.
- Kobashi M, Furudono Y, Matsuo R, Yamamoto T (2002). Central orexin facilitates gastric relaxation and contractility in rats. *Neurosci Lett* 332: 171–174.
- Kobayashi M, Nomura M, Fujihara H, Suzuki H, Otsubo H, Nishii H *et al.* (2009). Involvement of orexin-A on micturition reflex in normal and cyclophosphamide-induced cystitis bladder in rat. *Peptides* 30: 2348–2356.
- Kohsaka A, Watanobe H, Kakizaki Y, Suda T, Schiöth HB (2001). A significant participation of orexin-A, a potent orexigenic peptide, in the preovulatory luteinizing hormone and prolactin surges in the rat. *Brain Res* 898: 166–170.
- Kok SW, Roelfsema F, Overeem S, Lammers GJ, Strijers RL, Frolich M *et al.* (2002). Dynamics of the pituitary-adrenal ensemble in hypocretin-deficient narcoleptic humans: blunted basal adrenocorticotropin release and evidence for normal time-keeping by the master pacemaker. *J Clin Endocrinol Metab* 87: 5085–5091.
- Kok SW, Roelfsema F, Overeem S, Lammers GJ, Frolich M, Meinders AE *et al.* (2004). Pulsatile LH release is diminished, whereas FSH secretion is normal, in hypocretin-deficient narcoleptic men. *Am J Physiol Endocrinol Metab* 287: E630–E636.
- Kok SW, Roelfsema F, Overeem S, Lammers GJ, Frolich M, Meinders AE *et al.* (2005). Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. *Am J Physiol Endocrinol Metab* 288: E892–E899.
- Kotani A, Ikeda H, Koshikawa N, Cools AR (2008). Role of orexin receptors in the nucleus accumbens in dopamine-dependent turning behaviour of rats. *Neuropharmacology* 54: 613–619.
- Kotz CM (2006). Integration of feeding and spontaneous physical activity: role for orexin. *Physiol Behav* 88: 294–301.
- Kotz CM, Teske JA, Levine JA, Wang C (2002). Feeding and activity induced by orexin A in the lateral hypothalamus in rats. *Regul Pept* 104: 27–32.
- Krowicki ZK, Burmeister MA, Berthoud HR, Scullion RT, Fuchs K, Hornby PJ (2002). Orexins in rat dorsal motor nucleus of the vagus potentially stimulate gastric motor function. *Am J Physiol Gastrointest Liver Physiol* 283: G465–G472.
- Kukkonen JP (2013). Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. *Am J Physiol Cell Physiol* 304: C2–32.
- Kumar S, Szymusiak R, Bashir T, Rai S, McGinty D, Alam MN (2007). Effects of serotonin on perifornical-lateral hypothalamic area neurons in rat. *Eur J Neurosci* 25: 201–212.

- Lambe EK, Olausson P, Horst NK, Taylor JR, Aghajanian GK (2005). Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat. *J Neurosci* 25: 5225–5229.
- Lawrence AJ, Cowen MS, Yang HJ, Chen F, Oldfield B (2006). The orexin system regulates alcohol-seeking in rats. *Br J Pharmacol* 148: 752–759.
- de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE et al. (1998). The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci U S A* 95: 322–327.
- Lee MG, Hassani OK, Jones BE (2005). Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. *J Neurosci* 25: 6716–6720.
- Leininger GM, Opland DM, Jo YH, Faouzi M, Christensen L, Cappellucci LA et al. (2011). Leptin action via neurotensin neurons controls orexin, the mesolimbic dopamine system and energy balance. *Cell Metab* 14: 313–323.
- Li B, Chen F, Ye J, Chen X, Yan J, Li Y et al. (2010a). The modulation of orexin A on HCN currents of pyramidal neurons in mouse prelimbic cortex. *Cereb Cortex* 20: 1756–1767.
- Li Y, Gao XB, Sakurai T, van den Pol AN (2002). Hypocretin/Orexin excites hypocretin neurons via a local glutamate neuron-A potential mechanism for orchestrating the hypothalamic arousal system. *Neuron* 36: 1169–1181.
- Li Y, Li S, Sui N, Kirouac GJ (2009). Orexin-A acts on the paraventricular nucleus of the midline thalamus to inhibit locomotor activity in rats. *Pharmacol Biochem Behav* 93: 506–514.
- Li Y, Li S, Wei C, Wang H, Sui N, Kirouac GJ (2010b). Changes in emotional behavior produced by orexin microinjections in the paraventricular nucleus of the thalamus. *Pharmacol Biochem Behav* 95: 121–128.
- Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X et al. (1999). The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98: 365–376.
- Liu RJ, van den Pol AN, Aghajanian GK (2002). Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. *J Neurosci* 22: 9453–9464.
- Liu ZB, Song NN, Geng WY, Jin WZ, Li L, Cao YX et al. (2010). Orexin-A and respiration in a rat model of smoke-induced chronic obstructive pulmonary disease. *Clin Exp Pharmacol Physiol* 37: 963–968.
- Lopez M, Seoane LM, Tovar S, Nogueiras R, Dieguez C, Senaris R (2004). Orexin-A regulates growth hormone-releasing hormone mRNA content in a nucleus-specific manner and somatostatin mRNA content in a growth hormone-dependent fashion in the rat hypothalamus. *Eur J Neurosci* 19: 2080–2088.
- Lopez M, Nogueiras R, Tena-Sempere M, Dieguez C (2010). Orexins (hypocretins) actions on the GHRH/somatostatin-GH axis. *Acta Physiol* 198: 325–334.
- Louis GW, Leininger GM, Rhodes CJ, Myers MG, Jr (2010). Direct innervation and modulation of orexin neurons by lateral hypothalamic LepRb neurons. *J Neurosci* 30: 11278–11287.
- Lu J, Greco MA (2006). Sleep circuitry and the hypnotic mechanism of GABA drugs. *J Clin Sleep Med* 2: S19–S26.
- Lungwitz EA, Molosh A, Johnson PL, Harvey BP, Dirks RC, Dietrich A et al. (2012). Orexin-A induces anxiety-like behavior through interactions with glutamatergic receptors in the bed nucleus of the stria terminalis of rats. *Physiol Behav* 107: 726–732.
- Ma X, Zubcevic L, Bruning JC, Ashcroft FM, Burdakov D (2007). Electrical inhibition of identified anorexigenic POMC neurons by orexin/hypocretin. *J Neurosci* 27: 1529–1533.
- McAttee LC, Sutton SW, Rudolph DA, Li X, Aluisio LE, Phuong VK et al. (2004). Novel substituted 4-phenyl-1,3-dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. *Bioorg Med Chem Lett* 14: 4225–4229.
- Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G (2012). Multiple roles for orexin/hypocretin in addiction. *Prog Brain Res* 198: 79–121.
- Mair RG, Hembrook JR (2008). Memory enhancement with event-related stimulation of the rostral intralaminar thalamic nuclei. *J Neurosci* 28: 14293–14300.
- Malendowicz LK, Tortorella C, Nussdorfer GG (1999). Orexins stimulate corticosterone secretion of rat adrenocortical cells, through the activation of the adenylate cyclase-dependent signaling cascade. *J Steroid Biochem Mol Biol* 70: 185–188.
- Malendowicz LK, Hochol A, Ziolkowska A, Nowak M, Gottardo L, Nussdorfer GG (2001). Prolonged orexin administration stimulates steroid-hormone secretion, acting directly on the rat adrenal gland. *Int J Mol Med* 7: 401–404.
- Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M et al. (2001). Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* 435: 6–25.
- Matsumura K, Tsuchihashi T, Abe I (2001). Central orexin-A augments sympathoadrenal outflow in conscious rabbits. *Hypertension* 37: 1382–1387.
- Matsuzaki I, Sakurai T, Kunii K, Nakamura T, Yanagisawa M, Goto K (2002). Involvement of the serotonergic system in orexin-induced behavioral alterations in rats. *Regul Pept* 104: 119–123.
- Mavanji V, Teske JA, Billington CJ, Kotz CM (2010). Elevated sleep quality and orexin receptor mRNA in obesity-resistant rats. *Int J Obes* 34: 1576–1588.
- Mazzocchi G, Malendowicz LK, Gottardo L, Aragona F, Nussdorfer GG (2001). Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. *J Clin Endocrinol Metab* 86: 778–782.
- Mediavilla C, Cabello V, Risco S (2011). SB-334867-A, a selective orexin-1 receptor antagonist, enhances taste aversion learning and blocks taste preference learning in rats. *Pharmacol Biochem Behav* 98: 385–391.
- Meister B, Perez M, Daraio T (2013). Delta-like 1 homologue (DLK1) is a hypothalamus-enriched protein that is present in orexin-, but not melanin-concentrating hormone-containing neurones, of the lateral hypothalamic area. *J Neuroendocrinol* 25: 617–625.
- Methippara MM, Alam MN, Szymusiak R, McGinty D (2000). Effects of lateral preoptic area application of orexin-A on sleep-wakefulness. *Neuroreport* 11: 3423–3426.
- Mieda M, Hasegawa E, Kisanuki YY, Sinton CM, Yanagisawa M, Sakurai T (2011). Differential roles of orexin receptor-1 and -2 in the regulation of non-REM and REM sleep. *J Neurosci* 31: 6518–6526.
- Mileykovskiy BY, Kiyashchenko LI, Siegel JM (2002). Muscle tone facilitation and inhibition after orexin-A (hypocretin-1) microinjections into the medial medulla. *J Neurophysiol* 87: 2480–2489.
- Mileykovskiy BY, Kiyashchenko LI, Siegel JM (2005). Behavioral correlates of activity in identified hypocretin/orexin neurons. *Neuron* 46: 787–798.

- Mitsuma T, Hirooka Y, Mori Y, Kayama M, Adachi K, Rhue N *et al.* (1999). Effects of orexin A on thyrotropin-releasing hormone and thyrotropin secretion in rats. *Horm Metab Res* 31: 606–609.
- Miyasaka K, Masuda M, Kanai S, Sato N, Kurosawa M, Funakoshi A (2002). Central Orexin-A stimulates pancreatic exocrine secretion via the vagus. *Pancreas* 25: 400–404.
- Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, Scammell TE (2004). Behavioral state instability in orexin knock-out mice. *J Neurosci* 24: 6291–6300.
- Mochizuki T, Arrigoni E, Marcus JN, Clark EL, Yamamoto M, Honer M *et al.* (2011). Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. *Proc Natl Acad Sci U S A* 108: 4471–4476.
- Molik E, Zieba DA, Misztal T, Romanowicz K, Wszola M, Wierzbos E *et al.* (2008). The role of orexin A in the control of prolactin and growth hormone secretions in sheep – in vitro study. *J Physiol Pharmacol* 59 (Suppl 9): 91–100.
- Moreno G, Perello M, Gaillard RC, Spinedi E (2005). Orexin a stimulates hypothalamic-pituitary-adrenal (HPA) axis function, but not food intake, in the absence of full hypothalamic NPY-ergic activity. *Endocrine* 26: 99–106.
- Muroya S, Funahashi H, Yamanaka A, Kohno D, Uramura K, Nambu T *et al.* (2004). Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca²⁺ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus. *Eur J Neurosci* 19: 1524–1534.
- Muschamp JW, Dominguez JM, Sato SM, Shen RY, Hull EM (2007). A role for hypocretin (orexin) in male sexual behavior. *J Neurosci* 27: 2837–2845.
- Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, Kuwaki T (2007). Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. *J Appl Physiol* 102: 241–248.
- Nakamura T, Uramura K, Nambu T, Yada T, Goto K, Yanagisawa M *et al.* (2000). Orexin-induced hyperlocomotion and stereotypy are mediated by the dopaminergic system. *Brain Res* 873: 181–187.
- Nanmoku T, Isobe K, Sakurai T, Yamanaka A, Takekoshi K, Kawakami Y *et al.* (2000). Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells. *Biochem Biophys Res Commun* 274: 310–315.
- Naslund E, Ehrstrom M, Ma J, Hellstrom PM, Kirchgessner AL (2002). Localization and effects of orexin on fasting motility in the rat duodenum. *Am J Physiol Gastrointest Liver Physiol* 282: G470–G479.
- Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E (2000). Hypocretin (orexin) deficiency in human narcolepsy. *Lancet* 355: 39–40.
- Nishino S, Fujiki N, Ripley B, Sakurai E, Kato M, Watanabe T *et al.* (2001). Decreased brain histamine content in hypocretin/orexin receptor-2 mutated narcoleptic dogs. *Neurosci Lett* 313: 125–128.
- Nowak KW, Mackowiak P, Switonska MM, Fabis M, Malendowicz LK (2000). Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. *Life Sci* 66: 449–454.
- Nozu T, Kumei S, Takakusaki K, Ataka K, Fujimiya M, Okumura T (2011). Central orexin-A increases colonic motility in conscious rats. *Neurosci Lett* 498: 143–146.
- Olds J (1962). Hypothalamic substrates of reward. *Physiol Rev* 42: 554–604.
- Olds J, Milner P (1954). Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. *J Comp Physiol Psychol* 47: 419–427.
- de Oliveira CV, Ciriello J (2003). Cardiovascular responses to hypocretin-1 in nucleus ambiguus of the ovariectomized female rat. *Brain Res* 986: 148–156.
- de Oliveira CV, Rosas-Arellano MP, Solano-Flores LP, Ciriello J (2003). Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract. *Am J Physiol Heart Circ Physiol* 284: H1369–H1377.
- Overeem S, Kok SW, Lammers GJ, Vein AA, Frolich M, Meinders AE *et al.* (2003). Somatotrophic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. *Am J Physiol Endocrinol Metab* 284: E641–E647.
- Peever JH, Lai YY, Siegel JM (2003). Excitatory effects of hypocretin-1 (orexin-A) in the trigeminal motor nucleus are reversed by NMDA antagonism. *J Neurophysiol* 89: 2591–2600.
- Peng HY, Chang HM, Chang SY, Tung KC, Lee SD, Chou D *et al.* (2008). Orexin-A modulates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit. *Am J Physiol Endocrinol Metab* 295: E117–E129.
- Perez CA, Stanley SA, Wysocki RW, Havranova J, Ahrens-Nicklas R, Onyimba F *et al.* (2011). Molecular annotation of integrative feeding neural circuits. *Cell Metab* 13: 222–232.
- Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG *et al.* (1998). Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18: 9996–10015.
- Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y *et al.* (2000). A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. *Nat Med* 6: 991–997.
- Piper DC, Upton N, Smith MI, Hunter AJ (2000). The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. *Eur J Neurosci* 12: 726–730.
- Plaza-Zabala A, Martin-Garcia E, de Lecea L, Maldonado R, Berrendero F (2010). Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. *J Neurosci* 30: 2300–2310.
- van den Pol AN (1999). Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. *J Neurosci* 19: 3171–3182.
- van den Pol AN, Acuna-Goycolea C, Clark KR, Ghosh PK (2004). Physiological properties of hypothalamic MCH neurons identified with selective expression of reporter gene after recombinant virus infection. *Neuron* 42: 635–652.
- Prud'homme MJ, Lacroix MC, Badonnel K, Gougis S, Baly C, Salesse R *et al.* (2009). Nutritional status modulates behavioural and olfactory bulb Fos responses to isoamyl acetate or food odour in rats: roles of orexins and leptin. *Neuroscience* 162: 1287–1298.
- Pu S, Dhillon H, Moldawer LL, Kalra PS, Kalra SP (2000). Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor. *J Neuroendocrinol* 12: 827–832.
- Rachalski A, Alexandre C, Bernard JF, Saurini F, Lesch KP, Hamon M *et al.* (2009). Altered sleep homeostasis after restraint stress in 5-HTT knock-out male mice: a role for hypocretins. *J Neurosci* 29: 15575–15585.
- Rainero I, Gallone S, Valfre W, Ferrero M, Angilella G, Rivoiro C *et al.* (2004). A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. *Neurology* 63: 1286–1288.
- Rao Y, Lu M, Ge F, Marsh DJ, Qian S, Wang AH *et al.* (2008). Regulation of synaptic efficacy in hypocretin/orexin-containing

neurons by melanin concentrating hormone in the lateral hypothalamus. *J Neurosci* 28: 9101–9110.

Reti IM, Reddy R, Worley PF, Baraban JM (2002). Selective expression of Narp, a secreted neuronal pentraxin, in orexin neurons. *J Neurochem* 82: 1561–1565.

Rosin DL, Weston MC, Sevigny CP, Stornetta RL, Guyenet PG (2003). Hypothalamic orexin (hypocretin) neurons express vesicular glutamate transporters VGLUT1 or VGLUT2. *J Comp Neurol* 465: 593–603.

Russell SH, Kim MS, Small CJ, Abbott CR, Morgan DG, Taheri S *et al.* (2000). Central administration of orexin A suppresses basal and domperidone stimulated plasma prolactin. *J Neuroendocrinol* 12: 1213–1218.

Russell SH, Small CJ, Kennedy AR, Stanley SA, Seth A, Murphy KG *et al.* (2001). Orexin A interactions in the hypothalamo-pituitary gonadal axis. *Endocrinology* 142: 5294–5302.

Russell SH, Small CJ, Sunter D, Morgan I, Dakin CL, Cohen MA *et al.* (2002). Chronic intraparenchymal administration of orexin A in male rats does not alter thyroid axis or uncoupling protein-1 in brown adipose tissue. *Regul Pept* 104: 61–68.

Russo F, Pavone LM, Tafuri S, Avallone L, Staiano N, Vittoria A (2008). Expression of orexin A and its receptor 1 in the bovine urethrostomatic complex. *Anat Rec* 291: 169–174.

Sakamoto F, Yamada S, Ueta Y (2004). Centrally administered orexin-A activates corticotropin-releasing factor-containing neurons in the hypothalamic paraventricular nucleus and central amygdaloid nucleus of rats: possible involvement of central orexins on stress-activated central CRF neurons. *Regul Pept* 118: 183–191.

Sakurai T (2007). The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. *Nat Rev Neurosci* 8: 171–181.

Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H *et al.* (1998). Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573–585.

Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y *et al.* (2005). Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. *Neuron* 46: 297–308.

Samson WK, Taylor MM (2001). Hypocretin/orexin suppresses corticotroph responsiveness in vitro. *Am J Physiol Regul Integr Comp Physiol* 281: R1140–R1145.

Samson WK, Gosnell B, Chang JK, Resch ZT, Murphy TC (1999). Cardiovascular regulatory actions of the hypocretins in brain. *Brain Res* 831: 248–253.

Samson WK, Taylor MM, Follwell M, Ferguson AV (2002). Orexin actions in hypothalamic paraventricular nucleus: physiological consequences and cellular correlates. *Regul Pept* 104: 97–103.

Samson WK, Taylor MM, Ferguson AV (2005). Non-sleep effects of hypocretin/orexin. *Sleep Med Rev* 9: 243–252.

Saper CB, Scammell TE, Lu J (2005). Hypothalamic regulation of sleep and circadian rhythms. *Nature* 437: 1257–1263.

Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE (2010). Sleep state switching. *Neuron* 68: 1023–1042.

Sasaki K, Suzuki M, Mieda M, Tsujino N, Roth B, Sakurai T (2011). Pharmacogenetic modulation of orexin neurons alters sleep/wakefulness states in mice. *PLoS ONE* 6: e20360.

Satoh Y, Okishio Y, Azuma YT, Nakajima H, Hata F, Takeuchi T (2006). Orexin A affects ascending contraction depending on

downstream cholinergic neurons and descending relaxation through independent pathways in mouse jejunum. *Neuropharmacology* 51: 466–473.

Selbach O, Doreulee N, Bohla C, Eriksson KS, Sergeeva OA, Poelchen W *et al.* (2004). Orexins/hypocretins cause sharp wave- and theta-related synaptic plasticity in the hippocampus via glutamatergic, gabaergic, noradrenergic, and cholinergic signaling. *Neuroscience* 127: 519–528.

Selbach O, Bohla C, Barbara A, Doreulee N, Eriksson KS, Sergeeva OA *et al.* (2010). Orexins/hypocretins control bistability of hippocampal long-term synaptic plasticity through co-activation of multiple kinases. *Acta Physiol* 198: 277–285.

Seoane LM, Tovar SA, Perez D, Mallo F, Lopez M, Senaris R *et al.* (2004). Orexin A suppresses in vivo GH secretion. *Eur J Endocrinol* 150: 731–736.

Shahid IZ, Rahman AA, Pilowsky PM (2011). Intrathecal orexin A increases sympathetic outflow and respiratory drive, enhances baroreflex sensitivity and blocks the somato-sympathetic reflex. *Br J Pharmacol* 162: 961–973.

Sharf R, Sarhan M, Dileone RJ (2010). Role of orexin/hypocretin in dependence and addiction. *Brain Res* 1314: 130–138.

Shiraishi T, Oomura Y, Sasaki K, Wayner MJ (2000). Effects of leptin and orexin-A on food intake and feeding related hypothalamic neurons. *Physiol Behav* 71: 251–261.

Shirasaka T, Nakazato M, Matsukura S, Takasaki M, Kannan H (1999). Sympathetic and cardiovascular actions of orexins in conscious rats. *Am J Physiol* 277 (6 Pt 2): R1780–R1785.

Shirasaka T, Kunitake T, Takasaki M, Kannan H (2002). Neuronal effects of orexins: relevant to sympathetic and cardiovascular functions. *Regul Pept* 104: 91–95.

Shiuchi T, Haque MS, Okamoto S, Inoue T, Kageyama H, Lee S *et al.* (2009). Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. *Cell Metab* 10: 466–480.

Silveyra P, Lux-Lantos V, Libertun C (2007). Both orexin receptors are expressed in rat ovaries and fluctuate with the estrous cycle: effects of orexin receptor antagonists on gonadotropins and ovulation. *Am J Physiol Endocrinol Metab* 293: E977–E985.

Small CJ, Goubillon ML, Murray JF, Siddiqui A, Grimshaw SE, Young H *et al.* (2003). Central orexin A has site-specific effects on luteinizing hormone release in female rats. *Endocrinology* 144: 3225–3236.

Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA *et al.* (2001). SB-334867-A: the first selective orexin-1 receptor antagonist. *Br J Pharmacol* 132: 1179–1182.

Smith HR, Pang KC (2005). Orexin-saporin lesions of the medial septum impair spatial memory. *Neuroscience* 132: 261–271.

Smith PM, Connolly BC, Ferguson AV (2002). Microinjection of orexin into the rat nucleus tractus solitarius causes increases in blood pressure. *Brain Res* 950: 261–267.

Smith PM, Samson WK, Ferguson AV (2007). Cardiovascular actions of orexin-A in the rat subfornical organ. *J Neuroendocrinol* 19: 7–13.

Song CH, Xia JX, Ye JN, Chen XW, Zhang CQ, Gao EQ *et al.* (2005). Signaling pathways of hypocretin-1 actions on pyramidal neurons in the rat prefrontal cortex. *Neuroreport* 16: 1529–1533.

Spinazzi R, Rucinski M, Neri G, Malendowicz LK, Nussdorfer GG (2005a). Preproorexin and orexin receptors are expressed in

- cortisol-secreting adrenocortical adenomas, and orexins stimulate in vitro cortisol secretion and growth of tumor cells. *J Clin Endocrinol Metab* 90: 3544–3549.
- Spinazzi R, Ziolkowska A, Neri G, Nowak M, Rebuffat P, Nussdorfer GG *et al.* (2005b). Orexins modulate the growth of cultured rat adrenocortical cells, acting through type 1 and type 2 receptors coupled to the MAPK p42/p44- and p38-dependent cascades. *Int J Mol Med* 15: 847–852.
- Stiasny-Kolster K, Clever SC, Moller JC, Oertel WH, Mayer G (2007). Olfactory dysfunction in patients with narcolepsy with and without REM sleep behaviour disorder. *Brain* 130 (Pt 2): 442–449.
- Stone EA, Lin Y, Ahsan MR, Quartermain D (2005). Evidence of roles of central alpha1-adrenoceptors and epinephrine in orexin A-induced hyperactivity in mice. *Neurosci Lett* 381: 325–328.
- Sutcliffe JG, de Lecea L (2002). The hypocretins: setting the arousal threshold. *Nat Rev Neurosci* 3: 339–349.
- Switonska MM, Kaczmarek P, Malendowicz LK, Nowak KW (2002). Orexins and adipoinsular axis function in the rat. *Regul Pept* 104: 69–73.
- Takahashi K, Koyama Y, Kayama Y, Yamamoto M (2002). Effects of orexin on the laterodorsal tegmental neurones. *Psychiatry Clin Neurosci* 56: 335–336.
- Takahashi K, Arihara Z, Suzuki T, Sone M, Kikuchi K, Sasano H *et al.* (2006). Expression of orexin-A and orexin receptors in the kidney and the presence of orexin-A-like immunoreactivity in human urine. *Peptides* 27: 871–877.
- Takahashi N, Okumura T, Yamada H, Kohgo Y (1999). Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. *Biochem Biophys Res Commun* 254: 623–627.
- Takakusaki K, Habaguchi T, Saitoh K, Kohyama J (2004). Changes in the excitability of hindlimb motoneurons during muscular atonia induced by stimulating the pedunculopontine tegmental nucleus in cats. *Neuroscience* 124: 467–480.
- Takakusaki K, Takahashi K, Saitoh K, Harada H, Okumura T, Kayama Y *et al.* (2005). Orexinergic projections to the cat midbrain mediate alternation of emotional behavioural states from locomotion to cataplexy. *J Physiol* 568 (Pt 3): 1003–1020.
- Telegdy G, Adamik A (2002). The action of orexin A on passive avoidance learning. Involvement of transmitters. *Regul Pept* 104: 105–110.
- Terada J, Nakamura A, Zhang W, Yanagisawa M, Kuriyama T, Fukuda Y *et al.* (2008). Ventilatory long-term facilitation in mice can be observed during both sleep and wake periods and depends on orexin. *J Appl Physiol* 104: 499–507.
- Thakkar MM, Ramesh V, Strecker RE, McCarley RW (2001). Microdialysis perfusion of orexin-A in the basal forebrain increases wakefulness in freely behaving rats. *Arch Ital Biol* 139: 313–328.
- Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M *et al.* (2000). Reduced number of hypocretin neurons in human narcolepsy. *Neuron* 27: 469–474.
- Thorpe AJ, Kotz CM (2005). Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. *Brain Res* 1050: 156–162.
- Thorpe AJ, Mullett MA, Wang C, Kotz CM (2003). Peptides that regulate food intake: regional, metabolic, and circadian specificity of lateral hypothalamic orexin A feeding stimulation. *Am J Physiol Regul Integr Comp Physiol* 284: R1409–R1417.
- Thorpe AJ, Cleary JP, Levine AS, Kotz CM (2005a). Centrally administered orexin A increases motivation for sweet pellets in rats. *Psychopharmacology (Berl)* 182: 75–83.
- Thorpe AJ, Teske JA, Kotz CM (2005b). Orexin A-induced feeding is augmented by caloric challenge. *Am J Physiol Regul Integr Comp Physiol* 289: R367–R372.
- Tortorolo P, Yamuy J, Sampogna S, Morales FR, Chase MH (2003). Hypocretinergic neurons are primarily involved in activation of the somatomotor system. *Sleep* 26: 25–28.
- Tsujino N, Sakurai T (2009). Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. *Pharmacol Rev* 61: 162–176.
- Tsunematsu T, Kilduff TS, Boyden ES, Takahashi S, Tominaga M, Yamanaka A (2011). Acute optogenetic silencing of orexin/hypocretin neurons induces slow-wave sleep in mice. *J Neurosci* 31: 10529–10539.
- Walling SG, Nutt DJ, Lallies MD, Harley CW (2004). Orexin-A infusion in the locus ceruleus triggers norepinephrine (NE) release and NE-induced long-term potentiation in the dentate gyrus. *J Neurosci* 24: 7421–7426.
- Watanabe S, Kuwaki T, Yanagisawa M, Fukuda Y, Shimoyama M (2005). Persistent pain and stress activate pain-inhibitory orexin pathways. *Neuroreport* 16: 5–8.
- Watson SL, Watson CJ, Baghdoyan HA, Lydic R (2010). Thermal nociception is decreased by hypocretin-1 and an adenosine A1 receptor agonist microinjected into the pontine reticular formation of Sprague Dawley rat. *J Pain* 11: 535–544.
- Williams RH, Burdakov D (2008). Hypothalamic orexins/hypocretins as regulators of breathing. *Expert Rev Mol Med* 10: e28.
- Williams RH, Jensen LT, Verkhatsky A, Fugger L, Burdakov D (2007). Control of hypothalamic orexin neurons by acid and CO₂. *Proc Natl Acad Sci U S A* 104: 10685–10690.
- Willie JT, Chemelli RM, Sinton CM, Yanagisawa M (2001). To eat or to sleep? orexin in the regulation of feeding and wakefulness. *Annu Rev Neurosci* 24: 429–458.
- Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY *et al.* (2003). Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. *Neuron* 38: 715–730.
- Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ *et al.* (2011). Promotion of sleep by suvorexant—a novel dual orexin receptor antagonist. *J Neurogenet* 25: 52–61.
- Winsky-Sommerer R, Yamanaka A, Diano S, Borok E, Roberts AJ, Sakurai T *et al.* (2004). Interaction between the corticotropin-releasing factor system and hypocretins (orexins): a novel circuit mediating stress response. *J Neurosci* 24: 11439–11448.
- Winsky-Sommerer R, Boutrel B, de Lecea L (2005). Stress and arousal: the corticotrophin-releasing factor/hypocretin circuitry. *Mol Neurobiol* 32: 285–294.
- Wu X, Gao J, Yan J, Owyang C, Li Y (2004). Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat. *J Neurophysiol* 91: 1734–1747.
- Xi MC, Morales FR, Chase MH (2001). Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. *Brain Res* 901: 259–264.
- Xia J, Chen X, Song C, Ye J, Yu Z, Hu Z (2005). Postsynaptic excitation of prefrontal cortical pyramidal neurons by hypocretin-1/orexin A through the inhibition of potassium currents. *J Neurosci Res* 82: 729–736.
- Xia JX, Fan SY, Yan J, Chen F, Li Y, Yu ZP *et al.* (2009). Orexin A-induced extracellular calcium influx in prefrontal cortex neurons involves L-type calcium channels. *J Physiol Biochem* 65: 125–136.

- Xie XM, Wisor JP, Hara J, Crowder TL, LeWinter R, Khroyan TV *et al.* (2008). Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. *J Clin Invest* 118: 2471–2481.
- Xu R, Wang Q, Yan M, Hernandez M, Gong C, Boon WC *et al.* (2002). Orexin-A augments voltage-gated Ca²⁺ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes. *Endocrinology* 143: 4609–4619.
- Yamada H, Takahashi N, Tanno S, Nagamine M, Takakusaki K, Okumura T (2005). A selective orexin-1 receptor antagonist, SB334867, blocks 2-DG-induced gastric acid secretion in rats. *Neurosci Lett* 376: 137–142.
- Yamada H, Tanno S, Takakusaki K, Okumura T (2007). Intracisternal injection of orexin-A prevents ethanol-induced gastric mucosal damage in rats. *J Gastroenterol* 42: 336–341.
- Yamamoto T, Nozaki-Taguchi N, Chiba T (2002). Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. *Br J Pharmacol* 137: 170–176.
- Yamamoto T, Saito O, Shono K, Aoe T, Chiba T (2003a). Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. *Neurosci Lett* 347: 183–186.
- Yamamoto T, Saito O, Shono K, Hirasawa S (2003b). Activation of spinal orexin-1 receptor produces anti-allodynic effect in the rat carrageenan test. *Eur J Pharmacol* 481: 175–180.
- Yamanaka A, Sakurai T, Katsumoto T, Yanagisawa M, Goto K (1999). Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. *Brain Res* 849: 248–252.
- Yamanaka A, Kunii K, Nambu T, Tsujino N, Sakai A, Matsuzaki I *et al.* (2000). Orexin-induced food intake involves neuropeptide Y pathway. *Brain Res* 859: 404–409.
- Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M *et al.* (2003a). Hypothalamic orexin neurons regulate arousal according to energy balance in mice. *Neuron* 38: 701–713.
- Yamanaka A, Muraki Y, Tsujino N, Goto K, Sakurai T (2003b). Regulation of orexin neurons by the monoaminergic and cholinergic systems. *Biochem Biophys Res Commun* 303: 120–129.
- Yamanaka A, Muraki Y, Ichiki K, Tsujino N, Kilduff TS, Goto K *et al.* (2006). Orexin neurons are directly and indirectly regulated by catecholamines in a complex manner. *J Neurophysiol* 96: 284–298.
- Yamanaka A, Tabuchi S, Tsunematsu T, Fukazawa Y, Tominaga M (2010). Orexin directly excites orexin neurons through orexin 2 receptor. *J Neurosci* 30: 12642–12652.
- Yan J, He C, Xia JX, Zhang D, Hu ZA (2012). Orexin-A excites pyramidal neurons in layer 2/3 of the rat prefrontal cortex. *Neurosci Lett* 520: 92–97.
- Yoshida K, McCormack S, Espana RA, Crocker A, Scammell TE (2006). Afferents to the orexin neurons of the rat brain. *J Comp Neurol* 494: 845–861.
- Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H *et al.* (2001). Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. *Eur J Neurosci* 14: 1075–1081.
- Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E (2003). Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. *J Neurosci* 23: 3555–3560.
- Zhang J, Li B, Yu L, He YC, Li HZ, Zhu JN *et al.* (2011). A role for orexin in central vestibular motor control. *Neuron* 69: 793–804.
- Zhang W, Sunanaga J, Takahashi Y, Mori T, Sakurai T, Kanmura Y *et al.* (2010). Orexin neurons are indispensable for stress-induced thermogenesis in mice. *J Physiol* 588 (Pt 21): 4117–4129.
- Zheng H, Patterson LM, Berthoud HR (2007). Orexin signaling in the ventral tegmental area is required for high-fat appetite induced by opioid stimulation of the nucleus accumbens. *J Neurosci* 27: 11075–11082.
- Ziolkowska A, Spinazzi R, Albertin G, Nowak M, Malendowicz LK, Tortorella C *et al.* (2005). Orexins stimulate glucocorticoid secretion from cultured rat and human adrenocortical cells, exclusively acting via the OX1 receptor. *J Steroid Biochem Mol Biol* 96: 423–429.